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34.1 million adults (18 years or older) have diabetes (13.0% of US adults) according 
to the CDC (2020). Diabetes is complex and associated with comorbidities which requires 
both lifestyle changes and medication to successfully manage the condition (World Health 
Organization, 2016). The purpose of this dissertation is to investigate the engagement in, 
and impact of, a workplace diabetes control program while measuring clinical health 
biomarkers and healthcare utilization in a municipality. Secondary data analysis was 
conducted using a de-identified clinical dataset that was collected from the City of Austin 
(COA) Diabetes Control Program (DCP). Most participants enrolling in the COA DCP 
were engaged, completing three or more pharmacy visits during both 2018 (85%) & 2019 
(86%). Most participants during both 2018 (64%) & 2019 (59%) had baseline HbA1c 
values < 7%, signifying glycemic control, with averages for 2018 & 2019 respectively (6.7 
 1.3 & 6.9  1.3).  There were significant differences between 2018 & 2019 baseline 
values in body mass (2018: 98.1 22.3 kg; 2019: 97.1  21.1 kg), HbA1c (2018: 6.7 1.3; 
 v 
2019: 6.9  1.3), LDL (2018: 54.4  23.9 mg/dL; 2019: 49.8  22.3 mg/dL), total 
cholesterol (2018: 146.6 34.2 mg/dL; 2019: 137.2 34.9mg/dL) and triglycerides (2018: 
175.9 100.2 mg/dL; 2019: 144.790.6 mg/dL) (p<0.05). There was a trend of higher 
HbA1c and decreased engagement, but it was not statistically significant. Study two 
evaluated HbA1c change over time engaged in the COA DCP. Participants showed a 
significantly higher HbA1c in visit 3 in 2018 (6.950.l) than in visit 1 in 2018 (6.70.1) (t 
= -4.4, p = 0.0002; Participants showed a significantly higher HbA1c in visit 1 in 2019 (6.9 
 1.3) than in visit 1 in 2018 (6.70.1) (t = -3.0, p = 0.03). In 2019, participants engaged in 
the COA DCP significantly improved HbA1c from baseline (visit 1) (6.9  1.3) to visit 2 
(6.70.1) (t = 3.4, p = 0.01). These results show a trend of HbA1c increasing during the 
2018 COA DCP and HbA1c decreasing during the 2019 COA DCP. Study three evaluated 
cardiovascular clinical biomarkers while controlling for HbA1c and measured preventive 
healthcare utilization within the COA diabetic population. Three cardiovascular related 
clinical biomarkers (LDL, triglycerides, and total cholesterol) were significantly affected 
by year while controlling for HbA1c. LDL was significantly affected by year (t = -2.6, p = 
0.01). Participants had a significantly higher LDL in 2018 (65.2  1.1 mg/dl) compared to 
2019 (60.3  1.1 mg/dl) (t = 3.3, p < 0.01). Total cholesterol was significantly affected by 
year (t = -4.3, p <0.0001). Participants had a significantly higher total cholesterol in 2018 
(146  0.95 mg/dl) compared to 2019 (136  0.95 mg/dl) (t = 6.9 p < 0.0001). There was a 
significant interaction effect of visit and year on triglycerides (F = 4.9, p = 0.01). The 
triglycerides in 2018 decreased by each visit but increased from visit 1 to visit 2 in 2019. 
 vi 
However, significant differences were only found in visit 1 between 2018 (178  4.8) and 
2019 (145  4.8) (t = 4.9, p < 0.01). There was no significant interaction of visit and year 
on systolic blood pressure, HDL & Body Mass. Employees enrolled in the COA DCP 
completed significantly more preventive healthcare screenings than employees with 
diabetes not enrolled in the COA DCP. These studies help to better understand the 
population engaging in the COA DCP as well as evaluate clinical biomarkers in response 
to the COA DCP. Overall, the COA DCP population has a high percentage of participants 
with good glycemic control and cardiovascular clinical biomarkers within range. There 
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CHAPTER I: GENERAL INTRODUCTION 
 
34.1 million adults (18 years or older) have diabetes (13.0% of US adults) and 7.3 
million adults were not aware (undiagnosed) they had diabetes according to the CDC 
(2020). 19.7 million adults with diabetes are within the working age range of 18-64 years 
old and males have a slightly higher prevalence of diabetes than women (National Diabetes 
Statistics Report, 2020). New cases of diabetes were higher in Hispanics and non-Hispanic 
blacks compared to non-Hispanic whites and non-Hispanic Asians (National Diabetes 
Statistics Report, 2020). The percentage of adults who knew they had blood glucose levels 
in the pre-diabetic range doubled, but many adults with the condition are still unaware 
(National Diabetes Statistics Report, 2020). Cases of type 1 and type 2 diabetes have 
significantly increased in United States youth, ages 10-19 years old (National Diabetes 
Statistics Report, 2020). Rates of diabetes is rising in the youth population, and this 
generation will have to live with a chronic condition longer during their life, which 
increases the risk of comorbidities and healthcare costs if glycemic control is not achieved 
long-term.  
Diabetes is a major public health problem that strains the economic, physical, and 
mental well-being of America (Bommer et al., 2018). Excess medical costs per diabetic 
person increased from a 2012 estimate of $8,417 to a 2017 estimate of $9,601(National 
Diabetes Statistics Report, 2020). By 2030 it is expected diabetic related global costs will 




outcomes and reduce the risk of complications like cardiovascular disease (O’Connell & 
Manson, 2019). Workplace wellness programs are an effective setting to screen for 
diabetes and implement lifestyle interventions to reduce the burden of diabetes (De La 
Torre & Goetzel, 2016). 
Diabetes is a complex disease and is associated with comorbidities such as 
cardiovascular disease, obesity, and cognitive decline (World Health Organization, 2016). 
Endothelial dysfunction, which influences blood flow, may be one mechanism that is 
responsible for the increased risk of cardiovascular events in people with diabetes (Tabit 
et al., 2010).  Endothelial dysfunction might also be a contributing factor to diabetes related 
cognitive dysfunction (Biessels & Despa, 2018). Reducing cardiovascular risk factors such 
as hypertension and elevated lipids may also help prevent cognitive dysfunction (Biessels 
& Despa, 2018). Elevated glucose levels and insulin resistance may also be contributing 
factors for cognitive decline associated with diabetes (Biessels & Despa, 2018).  
Physical activity can reduce the risk for diabetes and comorbidities (Yang et al., 
2019). Physical activity impacts metabolic health in type 2 diabetes by increasing uptake 
and utilization of energy, improves insulin sensitivity and may reduce BMI (Yang et al.,). 
Physical activity is a cost-effective intervention and widely accessible. According to the 
CDC, 38% of the diabetic population is considered physically inactive and 89% of the 
diabetic population is overweight or obese (2020). Focusing on lifestyle changes to 
increase physical activity in the pre-diabetic and diabetic population can help reduce the 




Physical inactivity is related to increased risk of the most prevalent chronic diseases 
(National Center for Health Statistics, 2017). The shift in the American workforce is 
creating sedentary workplaces and is a feasible target for implementation of wellness 
initiatives to improve health outcomes and reduce the costs of healthcare (Bureau of Labor 
Statistics, 2016). Implementing a comprehensive workplace wellness program should 
target specific lifestyle changes that will reduce the risk of chronic disease as well as 
disease management and include proper evaluation to show positive health outcomes 
(Pronk et al., 2014; Grossmeier et al., 2010). Targeted goals such as increased physical 
activity or weight management based on multi-component interventions are shown to be 
more successful in eliciting long-term health changes (Schroer et al., 2013). Most large 
employers are self-funded, assuming the financial burden of unhealthy employees (Kaiser 
Family Foundation, 2019). Offering screening and lifestyle programs to reduce the risk of 
chronic disease through a workplace wellness program has the potential to reduce costs 
and improve long-term health outcomes (Yen et al., 2010). 
Many people with diabetes have comorbidities, and the screening, counseling and 
treatment needs exceed the time constraints of a physician visit (Kosecoff et al., 1990). 
Pharmacist-led medication therapy disease management (MTDM) programs have the 
autonomy to provide individualized diabetes education and counsel patients on lifestyle 
changes and medication adherence (Maeng et al., 2018). For example, a retrospective 
cohort study was conducted using electronic health records and insurance claims to 




2018). The results of the study showed that patients engaged in MTDM had lower rates of 
inpatient admissions and lower medical costs. This model has shown to improve clinical 
outcomes, healthcare utilization and lower medical costs and further research should 
evaluate how these programs can be integrated into comprehensive workplace wellness 
programs.  
Design and implementation of workplace wellness programs are unique to each 
institution. The more research can define best practices for workplace wellness programs, 
the more likely employers will see a positive return on investment. Support from managers 
and perceived social support increase participation rates (Lier et al., 2019). Establishing a 
wellness culture within the company is necessary to increase engagement and for the 
program to be successful. For example, will the employees be able to access wellness 
benefits during working hours or will they only be able to utilize them before or after work? 
When best practices are not used in the design or implementation of a workplace wellness 
program, outcomes such as engagement, health savings and improved health behaviors are 
negatively impacted (Pronk, 2014).  
Where workplace wellness programs exist, policies to promote the program and 
allow employees time at work to participate is critical for the success of the program (Ablah 
et al., 2019). Employees should be given time at work to take activity breaks or flex 
schedules to fit in exercise (Ablah et al., 2019). Increases in physical activity at work 
correlate with increases in willingness to work and psychological well-being (Silva et al., 




Measuring outcomes from workplace interventions is crucial to show benefits to 
both employers and employees participating in wellness programs. Wellness programs 
include a variety of benefits, including disease screening and management, tobacco 
cessation programs, health coaching, stress management programs, health education 
classes, and exercise classes. Evaluating wellness programs across companies is difficult 
because each employer offers a unique program and studies may be subjected to selection 
bias. Research should be conducted to determine effectiveness of the wellness program and 
how to adjust intervention or policies for maximum benefit (Carnethon et al., 2009). 
Municipal governments are experiencing a growing rise in health care costs (Pew 
Charitable Trusts, 2014; Benavides & David, 2010). Rising healthcare costs are one of the 
primary drivers for long-term financial strain on municipalities (Sabharwal, Kiel & Hijal-
Moghrabi, 2019). Wellness design and evaluation practices for municipalities face unique 
challenges due to city-wide office locations and diversity of professions (Morgan et al., 
2011). Fewer than half the cities reporting wellness programs report formal evaluations of 
their programs (Morgan et al., 2011). Limited publications about successful municipal 
wellness programs exist and this is an area of need for future research, especially if the 
funds to start the program are from taxpayer dollars (Sabharwal, Kiel & Hijal-Moghrabi, 
2019). 
Few studies have assessed the impact of comprehensive wellness programs in 
municipalities over time on health outcomes and healthcare savings. Designing, 




demonstrate positive health changes and employer savings long-term (Pronk, 2014). 
Wellness programs are commonly evaluated inclusively and individual components, such 
as physical activity or nutrition, are not evaluated for impact separately. Results from the 
study will impact public health by individually evaluating a MTDM program that is part 
of a comprehensive wellness program. The outcome of the evaluation will provide an 
understanding of engagement within this workplace wellness program as well as 
evaluating clinical biomarkers. Preventive healthcare utilization will also be understood 
among the diabetic population on the City of Austin insurance plan. These results will 
provide evidence of the engagement, impact on health outcomes and preventive healthcare 
utilization that can be used to improve this onsite wellness program and provide a baseline 




CHAPTER II:  PURPOSE AND HYPOTHESIS 
 
Study 1: To prospectively identify differences between clinical characteristics among 
participants actively enrolled in the 2018 & 2019 City of Austin (COA) Diabetes Control 
Program (DCP) model. 
Hypothesis 1: There will be statistically significant differences in participants 2018 and 
2019 baseline clinical measures. 
Hypothesis 2: Among participants, baseline HbA1c will significantly predict engagement 
in the City of Austin Diabetes Control Program. 
 
Study 2: Evaluate the effect of visit and year on HbA1c among engaged participants of the 
City of Austin Diabetes Control Program (Visit 1, 2, 3; Year 2018, 2019) 
Hypothesis 1: There will be a statistically significant difference between HbA1c levels 
between 2018 and 2019. 
Hypothesis 2: There will be a statistically significant decrease of HbA1c among three 
visits during 2019. 
 
Study 3: To evaluate the effect of year and visit on cardiovascular variables (Total 
Cholesterol, LDL, Body Mass, Systolic blood pressure, HDL, Triglycerides) while 
controlling for HbA1c & assess preventive healthcare utilization among employees with 
diabetes enrolled in the City of Austin Diabetes Control Program compared to employees 




Hypothesis 1: There will be a statistically significant association of cardiovascular 
biomarkers and time in the DCP while controlling for HbA1c.   
Hypothesis 2: Participants with diabetes enrolled in the 2019 COA DCP will complete 
significantly more preventive healthcare screenings compared to employees with diabetes 
not engaged in the 2019 DCP.  
Research Purpose 
 The purpose of this dissertation is to understand engagement in a municipal 
workplace diabetes control program and measure clinical biomarker changes. This research 
will also provide an evaluation of engagement in preventive healthcare utilization in people 
with diabetes on the City of Austin health insurance plan. The results will guide future 
research and changes needed to make this program more effective and sustainable long-
term. 
Significance of Study 
 One of the gaps in workplace wellness program research is understanding 
engagement in medication therapy disease management (MTDM) programs within 
municipalities and impact on clinical outcomes (Fazel et al., 2017). The proposed study 
will provide significant impact to public health by understanding workplace wellness 
engagement and clinical biomarkers in a city-wide disease management wellness program. 




improve the overall health of our nation while reducing the economic burden of rising 
healthcare costs (Carnthenon et al., 2009). 
Definition of Terms 
 
• Diabetes: A chronic health condition that impacts how your body turns food into 
energy. Three main types of diabetes, type 1, type 2, and gestational diabetes. 
(HbA1c= 6.5% or higher) (CDC) 
 
• Pre-Diabetes: Blood glucose levels higher than normal (HbA1c 5.7-6.4%) (ADA) 
 
• Hemoglobin A1c (HbA1c): The amount of glucose (sugar) attached to hemoglobin 
over three months. A measure of glycemic control (CDC). 
 
• Controlled diabetes mellitus or glycemic control: defined as HbA1c less than 7% 
(ADA). 
 
• Comorbidities: the simultaneous presence of two or more diseases or medical 
conditions in a patient. 
 
• Cardiovascular disease: According to the World Health Organization (WHO)- a 
group of disorders of heart and blood vessels that include: 
 
o Hypertension 
o Heart attack 
o Stroke 
o Peripheral vascular disease 
o Heart failure 
 
• Hypertension (High Blood Pressure): systolic blood pressure of 140 mmHg or 
higher or diastolic blood pressure of 90 mmHg or higher, (AHA). 
 
• Endothelial dysfunction: an impairment of the ability of the endothelium to 





• Workplace Wellness Program: “Workplace health programs are a coordinated and 
comprehensive set of health promotion and protection strategies implemented at 
the worksite that includes programs, policies, benefits, environmental supports, and 
links to the surrounding community designed to encourage the health and safety of 
all employees.”, (CDC) 
 
• Medication Therapy Disease Management Program (MTDM): distinct service or 
group of services provided by health care providers, including pharmacists, to 
ensure the best therapeutic outcomes for patients. MTDM includes five core 
elements: medication therapy review, a personal medication record, a medication-
related action plan, intervention or referral, and documentation and follow-up. 
(CDC) 
 
• Physically inactive: getting less than 10 minutes a week of moderate or vigorous 
activity in each physical activity category of work, leisure time and transportation 
(National Diabetes Statistics Report, 2020) 
 
• Overweight: BMI of 25.0 to 29.9 kg/m2 
 




CHAPTER III: LITERATURE REVIEW 
Introduction 
 
National Healthcare Expenditures rose to $3.5 trillion in 2017 and are expected to 
reach $6 trillion by 2027 (NHE-Fact-Sheet, 2019). 80% of large firms are self-funded, 
meaning the employer assumes the financial risk for the health claims of its employees, 
creating an incentive for employers to invest in wellness programs to reduce costs, improve 
productivity, morale, and overall health (Kaiser Family Foundation, 2019). 84% of large 
firms and 50% of small firms that offer health insurance benefits offer employee wellness 
programs (Kaiser Family Foundation, 2019). Wellness programs include a variety of 
benefits, including tobacco cessation programs, health coaching, stress management 
programs, health education classes, and exercise classes. The Affordable Care Act, passed 
in 2010, allows employers to offer incentives of up to 30% of the total cost of healthcare 
coverage, per employee plan, expanding the workplace wellness industry’s revenue to $8 
million (Jones, Molitor, Reif, 2018). Evaluating wellness programs across companies is 
difficult because each employer offers a unique program and studies may be subject to 
selection bias due to the observational nature of workplace wellness program evaluation. 
This literature review will explore workplace wellness program design, health impact and 
the weaknesses in measuring outcomes.  
Physical inactivity is the fourth leading risk factor for death worldwide and is 




and diabetes (National Center for Health Statistics, 2017). Overall, occupational physical 
activity has decreased in the United States and certain desk jobs such as software 
developers, accountants, and insurance sales agents report spending over 80% of their 
workday in a sedentary position (Bureau of Labor Statistics, 2016). A large percentage of 
the population spends most of their day working, making the workplace a prime place for 
an intervention. It is important to have the employer promote the intervention to make it 
successful, but also reduce the burden of healthcare costs associated with chronic diseases 
that can be prevented from lifestyle interventions. Measuring outcomes from workplace 
interventions is crucial to show benefits to both employers and employees participating in 
wellness programs. 
Diabetes and Cardiovascular Disease 
 
According to the American Diabetes Association, the estimated costs of diabetes in 
2017 was $327 billion (“Economic Costs”, 2018). According to the CDC, over 100 million 
American Adults are living with prediabetes or diabetes (“New CDC Report”, 2017). 
Obesity and sedentary behavior are risk factors for diabetes (Toledo et al., 2007). 
Moderate-intensity physical activity and weight loss have been shown to prevent and 
improve hyperglycemia. Toledo et al., conducted a lifestyle intervention that included 
moderate-intensity physical activity by walking on a treadmill for 30 minutes most days 
and dietary counseling for 16-20 weeks (2017). Post-intervention muscle biopsies showed 




Annesi & Johnson conducted a 6-month diet and physical activity intervention to measure 
effects on HbA1c and discovered that change in physical activity had greater effect on 
HbA1c than BMI (2013).  
Diabetes is complex and associated with comorbidities and requires both lifestyle 
changes and medication to manage the condition (World Health Organization, 2016). Self-
management of diabetes is important for reducing long-term effects of this chronic disease. 
Self-management is defined as, “The individual’s ability to manage the symptoms, 
treatment, physical, and psychosocial consequences and lifestyle changes inherent in living 
with a chronic condition. Efficacious self-management encompasses the ability to monitor 
one’s condition and to effect the cognitive, behavioral, and emotional responses necessary 
to maintain a satisfactory quality of life.” (Barlow, 2001; Barlow et al., 2002).  
Teaching self-management skills as well as checking on compliance with 
medication adherence should be incorporated into workplace wellness programs and has 
been shown to reduce HbA1c and reduce the risk of comorbidities (Gaede et al., 2003). 
Even though there is vast evidence proving the beneficial outcomes of managing diabetes 
through lifestyle and medication, only <10% of the adults in the US with diabetes have 
these risk factors controlled (Saydah , Fradkin & Cowie, 2004; Malik et al., 2007). 
The American Diabetes Association Standards of Diabetes Care recommends a 
risk-factor based approach to decide whether statin therapy is necessary to control 
cardiovascular risk in people with diabetes (2018). Three variables: age, previous 




overweight or obesity and family history of premature atherosclerotic cardiovascular 
disease (ASCVD) are used to stratify risk (“Standards of Medical Care in Diabetes”, 2018). 
In younger patients with no risk factors, lifestyle changes alone may be an appropriate 
intervention rather than statins. LDL-c is a reversible risk factor associated with 
cardiovascular morbidity and mortality (Bertoluci & Rocha, 2017). People with diabetes 
have higher cardiovascular disease (CVD) mortality and controlling LDL-c can reduce the 
CVD relative risk (Bertoluci & Rocha, 2017).  
Lifestyle changes can lower this risk for CVD. Masana et al., evaluated lifestyle 
choices that can reduce the risk for CVD, including diet, alcohol consumption, tobacco use 
and physical activity (2017). The Mediterranean diet pattern has been shown to reduce the 
risk for cardiovascular disease (Masana et al., 2017).  
Cardiovascular disease and physical activity share an inverse relationship and have 
several mediating factors, including inflammatory markers and blood pressure as major 
influencers. BMI and HbA1c have smaller influence but still have an impact on 
cardiovascular disease (Mora et al., 2007). High blood pressure effects 108 million 
Americans and is a risk factor for cardiovascular disease (Facts about Hypertension, 2020). 
Aerobic exercise reduces both systolic and diastolic blood pressure and is an integral part 
of lifestyle interventions (Elley, 2002).  
Muchandani et al., conducted a meta-analysis to evaluate cardio-metabolic markers 
post-physical activity intervention and discovered significant positive changes in body 




lipids and blood glucose (Muchandani et al., 2019). Future research should include 
biomarkers as primary outcomes and estimate power for significant results rather than 
include them as secondary outcomes (Muchandani et al., 2019). 
Modern Workforce 
The modern workforce is aging and poses a significant concern for employers to 
manage chronic disease and health complications of employees. In 2000, 13% of the labor 
force was 55 or older and is projected to increase to 20% of the workforce by 2020 
(Anderko et al., 2012). The population of workers in the United States is changing, but so 
is the type of work. During the 1960’s almost 50% of the jobs in the United States required 
moderate intensity physical activity compared to less than 20% in 2008 (Church et al., 
2011). The advancement of technology has created a more sedentary workforce (Church 
et al., 2011). Decreases in energy expenditure without compensation from calorie intake 
has influenced the obesity epidemic and increased the risk for chronic diseases (Goettler, 
Grosse, Sonntag, 2017). Overweight and obesity lead to short-term and long-term indirect 
costs for the employer in the form of absenteeism and presenteeism (Goettler et al., 2017). 
Wellness programs to target these populations in the changing U.S. workforce are still in 
their infancy and further research is needed to show the return on investment for the 
employers to reduce direct and indirect costs. 
In addition to the population of the workforce that is changing, so is the distribution 
of the workforce. With the advancement of technology more companies are implementing 




Government organizations have followed behind private sector wellness programs in 
wellness and diversity of programs offered according to Otenyo & Smith (2017). 
Geography influences the type of program implemented but also the services distributed 
throughout a city-wide wellness program (Otenyo & Smith, 2017). For example, cities with 
longer sunshine days and better weather may invest in a bikeshare program to increase 
physical activity, but other cities that have greater access to farms and fresh produce may 
focus on implementing “Farm to Work” programs that increase fruit and vegetable intake 
(Otenyo & Smith, 2017).  
Large, geographically distributed cities that include multi-site workplaces and 
varying professions have more challenges when implementing comprehensive workplace 
wellness programs (Kilpatrick et al., 2017). Kilpatrick et al., surveyed public sector 
employees in Australia and found that location, shift work and workload were all barriers 
to participate in workplace wellness. As the implementation of workplace wellness 
programs increase while the geographic distribution of the modern workforce expands, 
including more people teleworking, remote options must be available for employees that 
do not work at the primary site location where the program is offered. 
Incentives 
 
The Affordable Care Act approved the use of incentives to increase utilization of 
preventive care (Jones et al., 2018). This law allows employers to offer incentives to 




al., examined the impact of preventive and health promoting behaviors when incentives 
were offered by 39 different employers that had the same insurance carrier (2017). The 
impact of financial incentives increased preventive doctor visits, lipid panel and glucose 
screenings compared to baseline rates by 21 to 29% but had a smaller impact on cancer 
screenings such as mammograms and colorectal screenings, which increased by 5.5% and 
7.3% from baseline (2017).  
Cuellar et al., evaluated how incentives affect subgroup populations (Cuellar et al., 
2017). At baseline Hispanics and African Americans were less likely than whites to have 
preventive screenings and Asians were more likely than whites to have preventive 
screenings (Cueller et al., 2017). Incentives failed to narrow preventive service gaps among 
races and even widened the gap, because Asians’ use of preventive services increased 
(Cueller et al., 2017). Future studies should measure the impact of incentives on health 
disparities. 
Participation in wellness programs vary depending on the type of program offered 
and if incentives are available (Huang et al., 2016; Einav, Lee, Levin, 2018). Huang et al., 
conducted a study evaluating types of wellness programs offered, participation rates, and 
if participation rates changed when incentives were introduced (2016). Five types of 
wellness programs were classified as follows:  “Limited”- restricted offerings including 
screenings and some programs, but not disease-management programs. “Comprehensive”- 
wide range of programs including screening, lifestyle, and disease-management programs. 




management programs. “Intervention-focused”- lifestyle and disease management but few 
screenings. “Prevention-focused”- focus on screenings for unhealthy behaviors but limited 
disease-management (Huang et al., 2016).  
Employers that offer incentives experience a 22% higher participation compared to 
those employers without incentives (Huang et al., 2016). Comprehensive wellness 
programs have significantly higher participation regardless of incentives compared to other 
styles of wellness programs (Huang et al., 2016). Incentives increase the rate of 
participation the greatest in prevention-focused programs (Huang et al., 2016). This 
information is valuable when designing wellness programs because it can help target the 
type of services employers should offer as well as when an incentive will increase 
participation. Since comprehensive programs have the highest rate of participation and 
elicit the greatest increase from incentives, this can be used as a model for future wellness 
program design.  
Employer Savings 
 
Wellness programs may help employers save money in other ways besides direct 
change in medical costs. Providing a robust wellness program may provide a self-selection 
tool and attract healthy employees as well as boost retention of healthy employees (Jones 
et al., 2018). Jones et al., studied the types of employees that engage in wellness programs 
at a large university and discovered that employees with very high medical expenses and 




program (2018). Employees with higher medical expenses increased participation in 
wellness programs when monetary incentives were increased but increasing non-monetary 
incentives does not result in a higher program participation rate for this group (Jones et al., 
2018).  
Providing a wellness program increased the number of employees received a health 
screening and increased employees’ belief that management cares about their wellbeing 
(Jones et al., 2018). This randomized controlled trial did not show savings in healthcare 
spending or changes in productivity, but these results were based on one year of data, and 
health care savings and productivity changes may not occur until multiple years later. This 
study elucidates non-monetary benefits of onsite wellness programs including an increase 
in screenings and increase in belief of employers’ commitment to well-being, which may 
increase retention of healthy workers.  
Workplace Wellness 
 
Song and Baicker completed a cluster randomized trial to identify the effects of a 
multi-component workplace wellness program on economic and health outcomes in a large 
U.S. warehouse retail company (2019). This is one of the most recent comprehensive 
studies to look at the impact of workplace wellness programs on health and economic 
outcomes. Eight modules spanning the topics of nutrition, exercise, stress management and 
prevention were implemented over 18 months across 20 worksites. Outcomes measured 




and productivity and absenteeism (Song & Baicker, 2019). The workplace wellness 
program implemented consisted of mostly webinars and challenges that were incentivized 
with a total of $250 potential earnings across the program. The wellness program group 
had significantly higher rates of positive self-reported behaviors compared to the controls 
but there were no differences in clinical measures, health care spending, or productivity 
and absenteeism over an 18-month period (Song & Baicker, 2019).  
This study demonstrated the ability for workplace wellness interventions to 
improve health behaviors but return on investment for employers and improved health 
outcomes may not change in the short-term. A weakness of this study is that the wellness 
program is evaluated as a whole, rather than individual components. Individual elements, 
such as physical activity or nutrition, are not  evaluated for impact separately from the 
program. Future studies should continue to randomize treatment to reduce selection while 
still evaluating individual elements of a wellness program. Individual evaluation of specific 
programs separate from the entire wellness program will provide information about which 
aspects are most impactful for positive health outcomes and healthcare savings. 
Evaluating workplace wellness programs is difficult because most health outcomes 
change longitudinally, and these measures are difficult to capture due to turnover rates of 
employment. Thorndike et al. conducted a randomized controlled trial to determine if a 9-
month maintenance intervention following a ten-week workplace exercise and nutrition 
program could prevent weight regain (2012). The ten-week initial study resulted in 




improve outcomes at the one-year follow-up (Thorndike et al., 2012). 65% of weight loss 
from the ten-week intervention was maintained after one year (Thorndike et al., 2012). 
Engagement in the online tool, provided nine months after the ten-week intervention, was 
low but seemed to be effective for participants that utilized this tool (Thorndike et al., 
2012).  
Levy & Thorndike used the same study population from the 10-week intervention 
and compared healthcare spending one year pre-and-post intervention (2019). Following 
the 10-week nutrition and exercise wellness program there were no differences in medical 
spending one-year post-intervention (Levy & Thorndike, 2019). This is an example of a 
workplace intervention working to reduce cardiovascular risk factors in the short term, but 
long-term health outcomes and healthcare spending are not impacted (Thorndike et al., 
2012;  Levy & Thorndike, 2019). The intervention was only 10-weeks long and to induce 
long-term changes that will result in saved healthcare expenditures the program will have 
to target a specific set of risk factors for a longer time. Sustainable onsite wellness programs 
rather than short-term interventions should be further investigated to see the association 
with healthcare savings. 
Pharmacist-led medication therapy disease management (MTDM) is an effective 
intervention to improve HbA1c, systolic blood pressure, and LDL cholesterol in diabetic 
patients (Fazel et al., 2017). Pharmacists are integral in the interdisciplinary care team for 
diabetic patients within the healthcare system and wellness programs have started utilizing 




(Maeng et al., 2018). Pharmacists in these programs have the autonomy to provide 
individualized diabetes education and counsel patients on lifestyle changes and medication 
adherence (Maeng et al., 2018). A retrospective cohort study was conducted using 
electronic health records and insurance claims to evaluate the impact of a MTDM on 
healthcare utilization and cost of care (Maeng et al., 2018). The results of the study showed 
that patients engaged in MTDM had lower rates of inpatient admissions and lower medical 
costs. This model has shown to improve clinical outcomes, healthcare utilization and lower 
medical costs and further research is recommended to evaluate how these programs can be 
integrated into comprehensive workplace wellness programs.  
Engagement 
 
Workplace wellness programs have low rates of active engagement (Mattke et al., 
2013). Incentives have been shown to increase participation rates and may help to 
improve health behaviors in the short-term (Huang et al., 2016). Gibson et al., evaluated 
engagement in an online incentive-based wellness program and discovered that male 
employees ages 18-34 had the highest levels of engagement while male employees 
between 55-64 years of age had the lowest levels of engagement (2017). These 
employees worked for a large nondurable goods manufacturing company. The 
engagement for this program may have been specific to the working population and 
intervention design, making it difficult to have a uniform measure of engagement when 




Incentives have been shown to increase participation in wellness programs 
(Cuellar et al., 2017). Preferences for type of incentive to engage in different areas of 
wellness differs depending on socioeconomic status and demographics (Jenkins et al., 
2018). Surveying the population to determine interest in incentives for specific areas of 
wellness may help target participation for higher risk populations (Jenkins, 2018). 
Understanding the interest of incentives in the population can help employers increase 
engagement in wellness programs targeting specific health behavior changes. 
Grossmeir et al., evaluated factors that predicted employee participation, health 
and medical cost impact and found that incentives may not be predictive of population-
level health impact although they may increase participation (2020). Organizational and 
leadership support was the strongest predictor of participation and impact (Grossmeir et 
al., 2020). Well-designed workplace wellness programs cannot impact employees 
positively if there isn’t high participation.  
Lower socioeconomic status and race are established risk factors for diabetes and 
cardiovascular disease (Carnethon et al., 2009). Blue collar workers typically have higher 
stress and less access to workplace wellness programs (Carnethon et al., 2009). 
Employers should aim to reduce barriers to participation for these higher risk populations 
by offering workplace wellness programs that are available during working hours at 
various worksites and allowing employees to participate without having to take paid time 




Another barrier to participation is a concern over privacy and an employer having 
health-related sensitive information (Perrault, Hildenbrand & Rnoh, 2020). 
Communicating effectively that all health-related information will not be shared with 
employers or impact the employee’s job is important for increasing participation among 
employees that may be skeptical of workplace wellness programs. Perceived health status 
also impacts participation. Employees that perceive themselves as healthy reported not 
having interest in wellness programs (Perrault, Hildenbrand & Rnoh, 2020). Offering 
biometric screenings to allow employees to understand their health risks can help 
increase participation in targeted wellness programs to influence overall health. 
Engaging employees in workplace wellness programs that have the potential to 
improve health and can be sustainable long-term is a goal for not just employers but the 




“Presenteeism” is defined as “employees being present at work but unable to be 
fully engaged in the work environment” (Lack, 2011). In the United States, presenteeism 
costs surpass $180 billion annually, which is greater than the $118 billion costs of 
absenteeism (Levin-Epstein, 2005). Presenteeism is a measurable productivity loss that is 




Evidence supports that aerobic and muscle-strengthening activities significantly 
lower work limitations when compared to inactive employees (Walker et al., 2017). Long-
term changes in physical activity had an inverse relationship with presenteeism (Walker et 
al., 2017). The positive findings using health assessment data suggest that investing in 
workplace physical activity programs will have a positive return on investment for 
employers by reducing employee presenteeism. For every dollar spent on wellness 
programs, employee medical costs fall by $3.27 and absenteeism costs fall by $2.73 
(Baicker, Cutler, Song, 2010). 
Traditionally employers used absenteeism as an indicator of cost related to 
employee health, but recently presenteeism has been shown to be a greater financial loss 
for employers than absenteeism (Goetzel et al., 2004). Goetzel et al., reviewed cost of 
health, absenteeism and presenteeism for top ten health conditions in a large medical 
absence database combined with productivity surveys and found 18-60% of cost to be 
attributed to presenteeism (2004). There is a growing body of evidence supporting well-
designed and implemented wellness programs that may be able to produce a positive return 
on investment (Aldana, 2001; Henke et al., 2011). Evaluating presenteeism is multi-faceted 
and difficult to measure due to variability in scales and validity among different 
populations.  
Improving clinical outcomes is a major goal for disease management wellness 
programming. Kiel & McCord conducted a retrospective evaluation of a diabetes 




preventive care (2005). Mean HbA1c reduction was 1.6%  and for patients with an initial 
uncontrolled HbA1c the reduction was 2.7% (Kiel & McCord, 2005). The mean LDL 
reduction was 16 mg/dL and the frequency of adherence to preventive care improved. This 
program was effective at improving clinical markers.  
Lage & Boye determined that a 1% reduction in HbA1c resulted in a 2% reduction 
in all health care costs and a 13% reduction in diabetes related costs resulting in an annual 
cost saving of $429 and $736 (2020). Sustaining these HbA1c reductions have positive 
impacts on quality of life and long-term health savings (Coffey et al., 2002).  
Design and Evaluation 
 
Design and implementation of wellness programs are unique to each institution. 
Lier, Breuer & Dallmeyer, studied 61 companies and classified companies as white collar 
(43 companies) or blue collar (18 companies) to evaluate organizational factors that 
influence participation rates (2019). Support from managers and perceived social support 
impact participation rates (Lier, Breuer & Dallmeyer, 2019). Establishing a wellness 
culture within the company is necessary to increase engagement and for the program to be 
successful. When best practices are not used in the design or implementation of a 
workplace wellness program outcomes such as engagement, health savings and improved 
health behaviors are negatively impacted (Pronk, 2014).  
American College of Sports Medicine (ACSM) has published a best practice guide 




are needed to be successful. Leadership, as described above, is the first dimension in which 
organizational support and engagement are needed (Lier et al., 2019; Pronk, 2014). 
Relevance is the second dimension; the program needs to target the interests of the 
employees. Partnership between individual workers, the organization and community 
organizations are necessary to develop a successful wellness program. Comprehensiveness 
is key to seeing positive health outcomes and this element is usually missing in the 
literature. Programs should include health education, stress management workplace 
screenings, disease management and exercise (Pronk, 2014).  
Implementation and engagement are needed to facilitate a successful workplace 
wellness program and incentives are often used to increase engagement (Pronk, 2014). 
Communication can be used to target subgroups and send specific messages to brand the 
program. Data needs to be collected and used to evaluate the program for continued 
program improvement and compliance needs to be considered to manage health data and 
safety (Pronk, 2014).  
Best practice for designing wellness programs is important for effective results but 
best practice for evaluation of programs is critical for continued positive health outcomes 
and return on investment. Even workplace wellness programs that follow best practices 
may fail to yield a positive return on investment (ROI) one year after implementation 
(Grossmeier et al., 2010). Timelines for evaluation and continuous improvements based on 




Implementation and process evaluation should be conducted during the first 12 
months of programming to understand engagement in the wellness program (Grossmeier 
et al., 2010). Participant satisfaction, medication adherence, knowledge and motivation 
may be positively influenced during the first year, but it will most likely take 12-24 months 
to see an impact in self-esteem, life-style changes, and clinical outcomes (Grossmeier et 
al., 2010). Outcome evaluations are recommended to be conducted two to five years 
following the initiation of the workplace wellness program and include health care costs, 
presenteeism, absenteeism, productivity, retention and hopefully overall positive return on 
investment and impact on company culture (Grossmeier et al., 2010).  
Return on Investment (ROI) 
 
Comprehensive workplace wellness programs have been shown to provide a 
positive ROI long-term. Yen et al., evaluated the ROI of the Midwest Utility Company 
wellness program from 1999 to 2007 (2010). The comprehensive wellness program had 
1.7 times greater savings than costs over the course of 9 years and had a statistically 
significant annual savings of $180 per participant. The cumulative ROI shows an increase 
with longer participation within the program (Yen et al., 2010). ROI was calculated using 
the cost of implementing the program & incentives compared to changes in medical claims, 
pharmacy claims and cost of time away from work (Grossmeier et al., 2010). Baseline 




(Yen et al., 2010). This study highlights that when costs and savings of the wellness 
program are followed long-term, the ROI is positive.   
Long-term positive ROI and impact on health outcomes in response to well-
designed wellness programs has been shown in many studies, but just focusing on ROI 
may not capture the full benefit of the wellness program (De La Torre & Goetzel, 2016).   
Value of Investment 
Value of investment is a more robust measure of workplace wellness programs 
that may capture employee satisfaction, better talent, and higher levels of retention (De 
La Torre & Goetzel, 2016). Implementing workplace wellness programs can be seen as 
an investment for employers and fill a national void by providing screenings that can 
identify chronic conditions early and allow for lifestyle changes to prevent these 
conditions (Carnethon, 2009). To improve population health, a restructuring of focus 
towards preventive health and implementing wellness programs in a sustainable and 
scalable way is recommended (Cowart & Olson, 2019).  
Value added services are sought to decrease costs and promote wellness at a 
population level (Cowart & Olson, 2019). Cowart & Olson define value as Value= Health 
Outcome/ Cost of providing care (2019). The health outcome can be measured as 
survival, quality of life or patient perspective. The increase in value can be measured as 
outcomes improving when cost of care stays the same or decreases (Cowan & Olson, 
2019). Measuring health outcomes and quality of life provides a broader picture of 




Impact of COVID-19 
 
Coronavirus disease (COVID-19), which causes acute respiratory syndrome, has 
changed healthcare and the world. Older adults and people with pre-existing health 
conditions including diabetes, hypertension & obesity are at greater risk of hospitalization 
and death if infected with COVID-19 (Muniyappa & Gubbi, 2020). Mortality risk was 
found to be significantly higher in people with diabetes infected with COVID-19 
compared to patients without diabetes (Hussain et al., 2020). This highlights the need for 
greater prevention to reduce these conditions and different ways to reach these 
populations during a socially distant time. 
  Workplace wellness programs will have to find ways to reach populations using 
technology and incorporate preventive programs at a distance that are still engaging to 
employees. Margolis et al., conducted a cluster randomized clinical trial with patients that 
had uncontrolled blood pressure using home blood pressure telemonitoring and 
pharmacist case management (2013). The telemonitoring group had greater blood 
pressure control than the usual care group at 6 months and 12 months follow-up 
(Margolis et al., 2013). This is one example of how a wellness program can adapt using 
telemedicine and home monitoring and improve clinical outcomes. The COVID-19 
pandemic is forcing the health and wellness industry to reevaluate how they deliver care 






Unhealthy employees cause direct and indirect costs to the employer and preventive 
health is an important mitigator to chronic disease (Raghupathi, W., & Raghupathi, V, 
2018). 90% of the $3.5 trillion of healthcare costs are related to chronic and mental health 
conditions (Health and Economic Costs of Chronic Disease, 2019). Cardiovascular disease 
is the costliest chronic condition and can be prevented through healthy lifestyle changes 
(Stewart, Ricci, Chee, Morganstein, 2003).  
Physical inactivity is related to increased risk of the most prevalent chronic diseases 
(National Center for Health Statistics, 2017). The shift in the American workforce is 
creating sedentary workplaces and is a feasible target for implementation of wellness 
initiatives to improve health outcomes and reduce the costs of healthcare (Bureau of Labor 
Statistics, 2016). Implementing a comprehensive workplace wellness program should 
target specific lifestyle changes that will reduce the risk of chronic disease as well as 
disease management and have proper evaluation to show outcomes (Pronk et al., 2014; 
Grossmeier et al., 2010). Targeted goals such as increased physical activity or weight 
management based on multi-component interventions are shown to be more successful 
(Schroer, Haupt, Pieper, 2013). 
Policy to promote the wellness program and allowing employees time at work to 
participate is critical for the success of the program (Ablah et al., 2019). Employees should 




2019). Increases in physical activity at work correlate with increases in willingness to work 
and psychological well-being (Silva et al., 2019; Parker et al., 2019).  
Municipal governments are experiencing a growing rise in health care costs and 
most cities with over 10,000 residents report the use of wellness programs (Pew Charitable 
Trusts, 2014; Benavides & David, 2010). Wellness design and evaluation best practices for 
municipalities are similar to the workplace wellness best practices reviewed above but may 
face unique challenges due to city-wide office locations and diversity of professions 
(Morgan et al., 2011). Less than half the cities reporting wellness programs report formal 
evaluations of their programs (Morgan et al., 2011). Limited publications about successful 
municipal wellness programs exist and this is an area of need for future research, especially 
evaluating the health and cost impact if the funds to start the program are from taxpayer 
dollars (Morgan et al., 2011).  
Design and evaluation best practices will guide the implementation of a program 
that will be sustainable long-term and available year-round for participants to engage 
(Pronk, 2014, Grossmeier, 2010). Most of the workplace wellness interventions reviewed 
were implemented as online modules or classes rather than engaging activities and were 
offered 1-2 times per year (Jones et al., 2018; Thorndike et al., 2012; Morgan et al., 2011). 
Wellness champions offer social support and help guide the design and implementation of 
wellness programs (Wellness Champions, 2019). Wellness champions are employed 
volunteers that are intrinsically motivated to promote health (Wellness Champions, 2019). 




essential for engagement and retention of participants (Spoonheim, Pronk, 2016; Ablah et 
al., 2019). Benefits of workplace wellness programs include reducing healthcare costs, 
retention of healthy employees, improving morale and productivity (Berry, Mirabito, Baun, 
2010; Mattke et al., 2013; Mattke, Schnyer, Van Busum, 2012).   
The main challenge for evaluating wellness programs is lack of definite outcome 
measures for success. It is suggested that future research continue to assess the impact of 
comprehensive wellness programs over time on health outcomes, healthcare savings and 
presenteeism using a variety of measurement tools to reduce error. Individual components 
of wellness programs should be evaluated separately for impact and return on investment. 
The modern workforce is changing, and healthcare costs are rising. A comprehensive 
wellness program should be sustainable and available across many worksites. Designing, 
implementing, and evaluating workplace wellness programs should use best practices and 
demonstrate positive health changes and employer savings long-term.  
Background of the City of Austin Wellness Program 
 
 The City of Austin employs 17,120 persons and 65% of the population is male. 
The City of Austin is a self-insured entity and is responsible for paying the medical and 
pharmacy claims of the employees and dependents. Healthy Connections is the wellness 
program that is offered to all employees and includes 4 main components: “Know your 




of the program are incentivized and known as “Healthy Rewards” where the employee 
can earn up to $150 per year for participating.  
The “Know your Health Numbers” campaign involves extensive screening of the 
population with biometric screenings available at worksites throughout the city as well as 
promoting annual physical exams. This program is incentivized with 8 hours of paid 
leave once the employee completes their online health assessment following the 
screening or annual physical.  
“Get Active” involves onsite and remote physical activity classes during each 
quarter. Participants can earn up to four hours of paid leave for attending 10 of the 12 
classes in the quarter for up to two quarters throughout the year. The remote walking 
class requires participants to reach 50,000 steps in the week or complete 150 minutes of 
activity that can be tracked by an approved device or application.  
“Eat Well” includes the Blue Cross Blue Shield Program Naturally Slim available 
to employees and dependents at no cost. In addition to this self-paced program the City of 
Austin provides an onsite registered dietitian available for nutritional counseling to all 
employees free of charge.  
“Live Healthy” offers disease management programs including tobacco cessation 
classes and the diabetes control program (DCP), mammograms and flu shot clinics. 
Furthermore, there are fitness challenges and seminars offered throughout the year that 




 The City of Austin Diabetes Control Program started in 2015 and has increased to 
over 700 participants in 2020. This is a version of a Pharmacist-led medication therapy 
disease management (MTDM) intervention. The City of Austin has partnered with a local 
pharmacy chain to provide the screenings and education to participants. Employees, 
dependents, and retirees with a diabetes or prediabetes diagnosis can join the program 
free of charge.  
Participants are required to attend one visit per quarter for at least three quarters of 
the year to earn the incentivized coverage of medication to treat diabetes at zero cost. The 
incentive of diabetes medication at a $0 copay is activated after the first pharmacy visit 
during the year. Participants are required to attend 3 visits in a calendar year in order to 
stay eligible to participate in the program the following year. At each of these meetings 
there is a set curriculum that covers aspects of lifestyle management for diabetes that is 
tailored to each patient. The pharmacist also records, HbA1c, lipids, weight, and blood 
pressure at each visit. The curriculum covered during the 2019 pharmacy visits in the COA 
DCP program covers basic nutrition and physical activity benefits, preventive healthcare 
screenings and goal setting for long-term lifestyle changes. The primary focus for nutrition 
in the program is on glycemic control rather than cardiovascular disease prevention. In 
addition to these visits, City of Austin dependents have access to medical nutrition therapy 
with a certified diabetes educator or registered dietitian for zero cost. 
 As this program grows it is important to evaluate the clinical biomarkers and the 





CHAPTER IV: METHODS  
Overview 
This study was designed to measure engagement characteristics, clinical 
biomarkers, and healthcare utilization of a City of Austin (COA) Diabetes Control Program 
(DCP). Participants are City of Austin employees, dependents and retirees who voluntarily 
enrolled in the COA Diabetes Control Program during 2018 and 2019. Each participant 
functions as their own control comparing biomarkers from 2018 to 2019.  
Volunteers signed the informed consent included in Appendix B. Once consent was 
given, participants completed the educational requirements of the program. The clinical 
data was stripped of all protected health information (PHI) and provided a unique 
identifying number by a City of Austin employee prior to the data being shared with the 
principal investigator.  
The 2018 City of Austin Diabetes Control Program required an initial 8-hour 
diabetes education class followed by at least three Hemoglobin A1c (HbA1c) fingerstick 
measurements and cholesterol screenings in a calendar year. The 2019 City of Austin 
Diabetes Control Program dropped the initial 8-hour education class requirements and 
divided the education into four segments that are delivered by a pharmacist during visits 
each quarter (Appendix C). This education was tailored to the individual in response to 
their HbA1c result during the visit. Visit 1 includes baseline Hemoglobin A1c (HbA1c) 




setting. Visit 2 includes follow-up Hemoglobin A1c (HbA1c) fingerstick and cholesterol 
screening, treatment options and medication overview as well as education on the impact 
of nutrition and physical activity on glycemic control. Visit 3 includes follow-up 
Hemoglobin A1c (HbA1c) fingerstick and cholesterol screening, setting physical activity 
goals, learning how food impacts blood glucose levels and how to read a food label. Visit 
4 includes follow-up Hemoglobin A1c (HbA1c) fingerstick and cholesterol screening, 
reviewing previous education and assessing goals. The shift in this education delivery was 
in response to reducing the initial 8-hour education class, which could be a barrier to 
enrollment in the program due to the class only being offered during work hours. Pharmacy 
appointments are available during daytime, evenings, and weekends at various locations 
throughout the city, allowing more employees to access the program. It is of interest to 
understand if these changes to the design of the program impacted engagement and clinical 
biomarkers.  
Participants 
640 City of Austin employees, dependents and retirees enrolled in the City of 
Austin Diabetes Control Program insured by Blue Cross Blue Shield of Texas insurance. 
Exclusion criteria included participants with Medicare as a primary insurance policy, 
employees without a diagnosis of prediabetes or diabetes, and less than 18 years of age.  
In 2019, City of Austin reported 17,120 employees in 57 departments with 65% of the 
population being male. Self-reported statistics reveal 49% of the population identifies as 





Flyers for the City of Austin Diabetes Program were posted throughout City of 
Austin work buildings and sent digitally through promotional emails.  (Appendix A). The 
flyer was also available at City of Austin biometric screenings and given to employees that 
had elevated glucose levels at the time of screening.  
Data Management 
 A local pharmacy chain collects and retains biometric outcomes containing PHI in 
compliance with HIPAA standards. This data set was de-identified and provided to the PI 
from the COA. Data Use Agreement can be seen in Appendix D. IRB determined this study 
was not human subjects research (Appendix E). 
Research Design  
Secondary data evaluation from a prospective cohort of employees enrolled in the 
City of Austin Diabetes Program. This review included 640 employees enrolled in the City 
of Austin Diabetes Program during 2018 & 2019. A within-group study design was 




CHAPTER V:  STUDY #1 
Engagement in a Pharmacist-led Diabetes Medication Therapy Disease 
Management Program. 
Abstract 
Background: Municipal governments are experiencing a rise in healthcare costs. 
Medication Therapy Disease Management (MTDM) Programs have been shown to 
improve clinical outcomes and healthcare costs. The objective of this study is to explore 
the baseline clinical characteristics and engagement of participants enrolled in the City of 
Austin Diabetes Control Program. 
Methods: Secondary data evaluation from a prospective cohort enrolled in the City of 
Austin Diabetes Program. This review included 640 employees enrolled in the City of 
Austin Diabetes Program during 2018 & 2019. A within-group study design was 
incorporated, with participants serving as their own controls. 
Results: Most participants enrolling in the COA DCP were engaged, completing three or 
more pharmacy visits during both 2018 (85%) & 2019 (86%). Most participants had 
baseline HbA1c values < 7% at baseline during both 2018 (64%) & 2018 (59%) with 
averages for 2018 & 2019 respectively (6.7  1.3 & 6.9 1.3).  There were significant 
differences in HbA1c (2018: 6.7 1.3; 2019: 6.9  1.3), LDL (2018: 54.4  23.9mg/dL; 
2019: 49.8  22.3 mg/dL) and triglycerides (2018: 175.9 100.2 mg/dL; 2019: 
144.790.6 mg/dL) between 2018 & 2019 baseline values (p<0.05). There was a trend of 




Conclusion: In conclusion, most of the participants who enrolled in the COA DCP were 
considered engaged in the program, completing three or more visits during both 2018 
(85%) & 2019 (86%). 64% (2018) & 59% (2019) of the City of Austin employees 
enrolled in the Diabetes Control Program had baseline HbA1c levels that were considered 
controlled according to the American Diabetes Standard of Care, which is a higher 
percentage than previous reports of the general population. Understanding barriers to 
engagement, such has a higher HbA1c, is the first step in developing strategies to 





Health is linked to quality of life and productivity (Loeppke, 2008). Growing 
healthcare costs can be linked to chronic diseases driven by modifiable health risks. 
Reducing the burden of chronic disease can be done with engaging workplace wellness 
programs that foster a culture of health (Loeppke, 2008). Incentives can increase 
engagement and have been shown to increase savings but more importantly return a 
positive value on investment, which reflects the broader impact of wellness programs 
(Loeppke, 2008). 
Diabetes is responsible for over a trillion dollars of global economic burden 
(Bommer et al., 2017). A 1% reduction in HbA1c has been shown to reduce all-cause 
total health care costs by 2% and a 13% reduction in diabetes related healthcare costs 
(Lage & Boye, 2020). Health coaching and monetary incentives have been shown to 
improve glycemic control over 5 years compared to individuals not engaging in these 
type of wellness programs (Raymond et al., 2019). Medication adherence has been shown 
to reduce healthcare costs and prevent hospital stays (Lloyd et al., 2019). Reducing 
barriers to engagement was a key reason for the City of Austin to shift the educational 
program model from 2018 to 2019.  
The City of Austin implemented an onsite Diabetes Control Program in 2015 in 
conjunction with their healthcare provider. The program has continued to evolve and in 
2020 there were 700+ participants enrolled in the program. This program is highly 
incentivized by covering the cost of medication and testing supplies for engaged 




which required an initial 8-hour session of education on diabetes management and a 
minimum of 3 HbA1c checks with a registered nurse. The current program has adopted a 
Pharmacist-Led Medication Management Therapy model, which partners with a local 
pharmacy chain to provide quarterly HbA1c & lipid checks and education about diabetes 
self-management.  
The objective of this study is to evaluate engagement and clinical baseline values 
in an onsite MTDM Program. The working hypotheses are there will be statistically 
significant differences in participant characteristics at baseline between 2018 and 2019 
and among participants, there will be statistically significant differences in engagement 
related to baseline HbA1c values.  
At the end of the study, it is our expectation that we better understand the 
engagement and baseline clinical characteristics of the City of Austin Diabetes Control 
Program. This individual component of the greater evaluation will help to understand 
differences of engaged and non-engaged participants and direct future planning for 
increasing engagement and targeting participation in at risk populations. 
Methods 
Participants 
 640 City of Austin employees, retirees and dependents enrolled in the City of 
Austin Diabetes Control Program insured by Blue Cross Blue Shield insurance. 
Exclusion criteria includes participants with Medicare as a primary insurance policy, 




of Austin reported 17,120 employees in 57 departments with 65% of the population being 
male. Self-reported statistics reveal 49% of the population identifies as white, 30% 
Hispanic or Latino and 14% black or African American. 
Data Collection 
The City of Austin Diabetes Program partners with a local pharmacy chain to 
collect biomarkers of participants within the program. These datasets are shared with the 
City of Austin who stores the file in a secure PHI folder within their system. Deidentified 
datasets were provided from the City of Austin for analysis. 
Statistical Analysis 
Descriptive statistics were completed to understand baseline characteristics of the 
population. Descriptive Statistics are reported as mean  sd. Descriptive statistics were 
compared using Student’s t-test. Engagement was defined as participating in three or more 
visits and controlled diabetes mellitus was defined as HbA1c less than 7%. Logistic 
regression was used to analyze engagement with HbA1c as the predictor. Participants with 
two or fewer visits were defined as “disengaged” and coded as 0; those with three or four 
visits were defined as “engaged” and coded as 1. Logistic regression coefficients provide 
the change in the log odds of the outcome variable for a one unit increase in the predictor 









Participants’ characteristics are described in Table 1. The total number of 
participants was 640, with each variable sample size listed for the baseline values. Pairwise 
deletion was used for participants who had missing data or incorrect entries. In Table 2, 
the descriptive statistics were completed using a listwise deletion, leading to a total sample 
size of 293. There were not significant differences in the baseline values between the 
pairwise deletion sample and listwise deletion sample. Most participants had baseline 
HbA1c values < 7% at baseline with averages for 2018 & 2019 respectively (6.7  1.3 & 
6.9  1.3). There were significant differences between 2018 & 2019 baseline values in body 
mass (2018: 98.1 22.3 kg; 2019: 97.1  21.1 kg), HbA1c (2018: 6.7 1.3; 2019: 6.9  
1.3), LDL (2018: 54.4  23.9 mg/dL; 2019: 49.8  22.3 mg/dL), total cholesterol (2018: 
146.6 34.2 mg/dL; 2019: 137.2 34.9mg/dL) and triglycerides (2018: 175.9 100.2 
mg/dL; 2019: 144.790.6 mg/dL) between groups (p<0.05).  
 




2018 Baseline 2019 Baseline 











34.2  7.6 
6.7  1.3 
54.4  23.9 
175.9 100.2 
126.9  17.0 
33.9  7.0 
6.9  1.3 * 
49.8  22.3 * 
144.7  90.6 * 
127.1  17.3 
Diastolic BP 418 76.9 10.8 76.6 11.5 
HDL 300 64.6 26.5 64.2  25.1 
Total Cholesterol  418 146.634.2 137.234.9* 
 Note: Data are reported as meansd (*) Significantly different 
between groups, p < .05 as performed with the T-Statistic 
BMI = body mass index; HbA1c = glycated hemoglobin; HDL = high-density lipoproteins LDL = 











2018 Baseline 2019 Baseline 






34.6  7.8 
6.6  1.2 
55.7  17.9 
163.0 71.5 
125.8  16.7 
34.4  7.3 
6.8  1.2 * 
52.2  24.1 * 
135.9  63.7 * 
126.7 18.0  





64.4  25.1 
143.2 31.1* 
   
 
Note: Data are reported as meansd (*) Significantly different between groups, p < .05 as 
performed with the T-Statistic. BMI = body mass index; HbA1c = glycated hemoglobin; HDL = 
high-density lipoproteins LDL = low-density lipoproteins; BP= blood pressure.  
 
Figure 1 shows the total number of participants at each visit throughout the program. The 
number of unique participants completing each visit can be seen in Figure 2. 2019 visit 3 
had the highest number of people compared to very few people only attending visit 1 or 2 
during both years. Most of the participants who enrolled were considered engaged in the 















Figure 1. Flow of participants through the City of Austin Diabetes Control Program during 




2018 COA DCP 
N= 566 at Visit 1 
2019 COA DCP 
N= 640 at Visit 1 
2019 COA DCP 
N= 593 at Visit 2 
2018 COA DCP 
N= 525 at Visit 2 
2018 COA DCP 
N= 478 at Visit 3 
2019 COA DCP 
N= 549 at Visit 3 
2018 COA DCP 
N= 214 at Visit 4 
2019 COA DCP 




Figure 2. Number of Unique City of Austin Diabetes Control Program Participants in their 
Final Visit  
 
 
Most participants had a controlled HbA1c at baseline during both 2018 (64%) & 2019 
(59%) (Table 3).  
 
Table 3. Glycemic Control and Engagement in City of Austin Diabetes Control Program 
 
 
Table 4 describes the engagement for 2018 & 2019 participants based on 
glycemic control. In 2018 & 2019 more engaged participants have a controlled HbA1c at 













































 2018  2019  
Total number of participants 564 640 
Engaged(≥3 visits) 85% 86% 
HbA1c <7% at baseline 64% 59% 




was 6.0  0.6 & 6.1  0.6 in 2019. The average HbA1c for employees with uncontrolled 
diabetes at baseline was 8.1  1.1 in 2018 & 2019. (Table 4). 
 









HbA1c ≥7% 2018 
baseline 
HbA1c ≥7% 2019 
baseline 











33.5  7.2 
6.0  0.6 
59.0   29.0 
170.0  90.8 
127.6  17.5 
33.8  7.0 
6.1  0.6  
53.2  15.2 
141.9  90.7  
126.5  17.5 
35.6  7.6 
8.1  1.1 
57.1  21.1 
190.7  115.2 
125.5  16.3 
34.1  6.9 
8.1  1.1 
49.6  13.7 
151.7 90.9 
128.1  16.9 





63.9  24.7 
144.4  30.3 
65.0  23.8  
137.9  35.1 
66.6  30.0 
152.1  39.8 
63.0  27.4 
137.0  34.8 
 
      
  Note:   
BMI = body mass index; HbA1c = glycated hemoglobin; HDL = high-density lipoproteins LDL = 
low-density lipoproteins; BP= blood pressure.  
 
In 2018 & 2019, a greater percentage of participants had a baseline HbA1c ≥7% 
that were not engaged (< 3 visits). In 2018 & 2019, there was a higher percentage of 
participants that had a controlled HbA1c at baseline in people considered engaged 










Table 5. Engagement by Glycemic Control in the City of Austin Diabetes Control Program 
2018 DCP n=564 HbA1c < 7% HbA1c ≥7% 
Engaged (≥3 visits) 66% 34% 
Not Engaged (< 3 visits) 55% 45% 
   
2019 DCP n=640 HbA1c< 7% HbA1c ≥7% 
Engaged (≥3 visits) 60% 40% 
Not Engaged (< 3 visits) 54% 46% 
   
 
In 2018 & 2019 there were more participants with glycemic control engaged in the COA 
DCP compared to participants not engaged in the COA DCP (Table 6).  
 
Table 6. Frequency Distribution of Engagement and Glycemic Control in the City of Austin 
Diabetes Control Program 
2018 DCP n=564 HbA1c < 7% HbA1c ≥7% 
Engaged (≥3 visits) 313 164 
Not Engaged (< 3 visits) 48 39 
   
2019 DCP n=640 HbA1c< 7% HbA1c ≥7% 
Engaged (≥3 visits) 329 220 
Not Engaged (< 3 visits) 49 42 
   
 
Participants who had a controlled HbA1c at baseline in 2018 had 55% higher odds 
of being engaged in the COA DCP compared to participants that did not have a controlled 
HbA1c at baseline, 95% CI [0.98, 2.46]. Participants who had a controlled HbA1c at 
baseline in 2019 had 28% higher odds of being engaged in the COA DCP compared to 
participants that did not have a controlled HbA1c at baseline, 95% CI [0.82, 2.00] (Figure 
2). Participants who had a controlled HbA2c had higher odds of being engaged although it 












There is a trend of higher HbA1c at baseline and lower engagement in the Diabetes 
Control Program. For a one unit increase in HbA1c, the log odds of being engaged 
decreases by 0.1 0.1. However, it did not reach statistical significance (z value = -1.9, p = 
0.06). Controlled or uncontrolled HbA1(A1c <7; A1c ≥7) was not a predictor of 
engagement. 
Discussion 
This study explored the baseline clinical characteristics and engagement of 
participants enrolled in the City of Austin Diabetes Program. 64% (2018) & 59% (2019) 
of the City of Austin employees enrolled in the Diabetes Control Program had baseline 
HbA1c levels that were considered controlled according to the American Diabetes 



















from the National Health and Nutrition Examination Survey (NHANES) was evaluated to 
determine percentage of adults who meet clinical guidelines set by the American Diabetes 
Association (ADA) Clinical practice recommendations between 1999-2002 (Resnick et al., 
2006). 50% of adults met the HbA1c target of less than 7% in this survey (Resnick et al., 
2006). The City of Austin population engaging in the Diabetes Control Program have better 
glycemic control than the greater American population (National diabetes Statistics Report, 
2020). 
Among participants in the 2018 & 2019 COA DCP there were statistically 
significant differences between baseline measures of HbA1c, LDL and triglycerides. 
Participants had higher baseline LDL (2018: 54.4  23.9; 2019: 49.8  22.3) and 
triglycerides (2018: 175.9 100.2; 2019: 144.7  90.6) in 2018  compared to 2019 and 
lower baseline HbA1c in 2018 compared to 2019 (2018: 6.7  1.3; 2019: 6.9  1.3). It 
would be expected that participants would have better clinical measures at baseline during 
the 2019 program compared to the 2018 baseline measures because they had already 
completed a year of the COA DCP with quarterly visits to measure these values and the 
initial 8-hour education course provided at the beginning of the 2018 program. The 
quarterly visits during the 2018 year did not have the structured education that the 2019 
program provided. The HbA1c baseline value increased from 2018 to 2019, meaning the 
2018 COA DCP did not produce improved glycemic control following 1 year of 
engagement in the program.  
Participants with better glycemic control at baseline also had better cardiovascular 
clinical values, specifically triglyceride levels, at baseline during 2018 and 2019 (Table 3). 
Elevated triglycerides are strongly associated with poor glycemic control (Zheng et al., 




but this did not reach statistical significance. People with poor glycemic control are the 
primary population that COA wants to engage in the program due to higher healthcare costs 
compared to low risk employees (Goetzel et al., 2020).  
Most of the participants who enrolled in the COA DCP were considered engaged 
in the program, completing three or more visits during both 2018 (85%) & 2019 (86%). 
Few participants only attend one or two visits (Figure 1). Another disease management 
program offered by a large employer found that 71% of employees dropped out of the 
program during the first year (Lynch et al., 2006). The COA requires a minimum of three 
visits to earn the incentive of $0 copay for diabetes medication and supplies. This incentive 
may be the reason for the high percentage of engagement in the program annually. 
Measuring the impact of the incentive on engagement is of interest for future research. 
Surveying participants about medication or asking the pharmacist to include this 
information on the report is recommended to evaluate medication usage and change during 
participation in the COA DCP. 
Understanding barriers to engagement, such has a higher HbA1c, is the first step in 
developing strategies to increase engagement in the targeted population. Future research 
should evaluate sociodemographic factors in addition to baseline clinical data to better 
understand the population engaging in the COA DCP. Increasing outreach and awareness 
of the COA DCP may increase participation in the DCP. Participants that have higher 
HbA1c at baseline may be targeted for follow-ups to try to increase engagement in the 






CHAPTER VI: STUDY #2 
Evaluating HbA1c Changes in Response to a Pharmacist Led Medication Therapy 
Disease Management Program (MTDM). 
Abstract 
Background: Diabetes is a major public health problem that strains the economic, 
physical, and mental well-being of America (Bommer et al., 2018). Early detection and 
treatment of diabetes can improve health outcomes. The objective of this study is to 
evaluate the changes in HbA1c in an employee wellness MTDM Program. 
Methods: Secondary data evaluation from a prospective cohort enrolled in the City of 
Austin Diabetes Program. This review included 640 employees, retirees and dependents 
enrolled in the City of Austin Diabetes Program during 2018 & 2019. A within-group 
study design was incorporated, with participants serving as their own controls. HbA1c 
change over time engaged in the COA DCP was evaluated. 
Results: Participants showed a significantly higher HbA1c in visit 3 in 2018 (6.950.1) 
than in visit 1 in 2018 (6.70.1) (t = -4.4, p = 0.0002; Participants showed a significantly 
higher HbA1c in visit 1 in 2019 (6.90.1) than in visit 1 in 2018 (6.70.1) (t = -3.0, p = 
0.03). In 2019, participants engaged in the COA DCP significantly improved HbA1c 
from baseline (visit 1) (6.90.1) to visit 2 (6.70.1) (t = 3.4, p = 0.01). 
Conclusion: There is a trend of HbA1c increasing during the 2018 COA DCP and HbA1c 
decreasing during the 2019 COA DCP. The 2018 COA DCP did not improve glycemic 




participants had an HbA1c that was considered controlled at baseline, therefore, significant 
decreases in HbA1c during 2019, even small, implies the COA DCP is successful. Long-






Currently one in three American adults have prediabetes and one in 10 have 
diabetes (National Diabetes Statistics Report, 2020).  Diabetic complications have a 
significant impact on an individual’s quality of life (Lloyd, Sawyer & Hopkinson, 2001). 
Early diagnosis and intervention to prevent these complications can have a profound 
impact on morbidity and mortality.  
Self-insured employers are responsible for most employee’s healthcare claims and 
can benefit from investing in workplace wellness programs to prevent and manage chronic 
disease (Aldana et al., 2006). Self-management skills are important in controlling blood 
glucose levels and implementing healthy lifestyle changes in people with diabetes. 
Pharmacist-Led Medication Therapy Disease Management programs have been shown to 
be effective at reducing HbA1c levels through teaching self-management skills and 
education surrounding diabetes management and lifestyle changes. (Cranor & Christensen, 
2003). 
Currently, there is not a standard curriculum or timeline of visits established for a 
MTDM program (Frederick et al., 2020).  Patients who have been seeing a provider 
consistently for years may be able to maintain their HbA1c reductions with visits every 3-
6 months (Frederick et al., 2020).  Ko et al., evaluated a Pharmacist-Led Medication 
Management program in the Texas region and found that people with diabetes enrolled in 
the program had greater reductions in HbA1c compared to patients following a standard 




 The objective of this study is to evaluate the changes in HbA1c of a workplace 
MTDM Program. The central hypothesis is that the DCP will improve HbA1c. The 
working hypotheses are there will be a statistically significant difference between HbA1c 
levels between 2018 and 2019 and there will be a statistically significant decrease of 
HbA1c among three visits during 2019. Our approach to testing the working hypothesis 
will be to conduct a secondary data evaluation from a prospective cohort enrolled in the 
City of Austin Diabetes Program. The rationale for this study is that the current HbA1c 
change in participants is unknown. Evaluation of clinical markers in this MTDM program 
will help to understand if the program is effective at improving HbA1c. At the end of this 
study, it is our expectation that we understand the association between engagement in the 
City of Austin Diabetes Control Program and HbA1c control. This knowledge will help to 
understand the relationship between HbA1c control, and the time spent engaged in the 
intervention. 
Methods 
Secondary data analysis was conducted using a de-identified clinical dataset that 
was collected from the City of Austin Diabetes Program.  A within- group study design 
was incorporated, with participants serving as their own controls.  
Participants 
640 City of Austin employees, retirees and dependents engaged in the Diabetes 
Control Program insured by Blue Cross Blue Shield insurance during 2018 & 2019. 




employees without a diagnosis of diabetes, and less than 18 years of age. In 2019, City of 
Austin reported 17,120 employees in 57 departments with 65% of the population being 
male. Self-reported statistics reveal 49% of the population identifies as white, 30% 
Hispanic or Latino and 14% black or African American. 
 
Data Management  
 The City of Austin (COA) Diabetes Control Program (DCP) partners with a local 
pharmacy chain to collect biomarkers of participants within the program. These datasets 
are shared with the City of Austin wellness team who stores the file in a secure PHI folder 




Descriptive statistics were completed to understand baseline characteristics of the 
population. Descriptive Statistics are reported as mean  sd. Descriptive statistics were 
compared using Student’s t-test (= 0.05). Two-way repeated measures ANOVA was used 
to evaluate HbA1c change in participants engaged in the 2018 and 2019 COA DCP. Post-
hoc analysis using Tukey Method was used to determine if statistical significance exists. 








Participants’ characteristics are described in Table 7. The total number of 
participants was 640, with each variable sample size listed for the baseline values. Pairwise 
deletion was used to remove missing data or incorrect entries. Most participants had 
baseline HbA1c values < 7% at baseline with averages for 2018 & 2019 respectively (6.7 
 1.3 & 6.9  1.3). There were significant differences between 2018 & 2019 baseline values 
in body mass (2018: 98.1 22.3 kg; 2019: 97.1  21.1 kg), HbA1c (2018: 6.7 1.3; 2019: 
6.9  1.3), LDL (2018: 54.4  23.9 mg/dL; 2019: 49.8  22.3 mg/dL), total cholesterol 
(2018: 146.6 34.2 mg/dL; 2019: 137.2 34.9mg/dL) and triglycerides (2018: 175.9 
100.2 mg/dL; 2019: 144.790.6 mg/dL) between groups (p<0.05). 
 




2018 Baseline 2019 Baseline 











34.2  7.6 
6.7  1.3 
54.4  23.9 
175.9 100.2 
126.9  17.0 
33.9  7.0 
6.9  1.3 * 
49.8  22.3 * 
144.7  90.6 * 
127.1  17.3 
Diastolic BP 418 76.9 10.8 76.6 11.5 
HDL 300 64.6 26.5 64.2  25.1 
Total Cholesterol 418 146.634.2 137.234.9* 
 Note: Data are reported as meansd (*) Significantly different 
between groups, p < .05 as performed with the T-Statistic 
BMI = body mass index; HbA1c = glycated hemoglobin; HDL = high-density lipoproteins LDL = 
low-density lipoproteins; BP= blood pressure.  
 
There was a significant interaction between visit and year (F=12.98, P <0.002). 
Participants showed a significantly higher HbA1c in visit 1 in 2019 (6.90.1) than in visit 




HbA1c in visit 2 in 2018 (6.90.1) than in visit 2 in 2019 (6.70.1) (t = 3.12, p = 0.02; 
Figure 3). Participants showed a significantly higher HbA1c in visit 3 in 2018 (6.950.1) 
than in visit 3 in 2019 (6.80.1) (t = 3.3, p = 0.01; Figure 3). Participants showed a 
significantly higher HbA1c in visit 1 in 2019 (6.90.1) than in visit 2 in 2019 (6.70.1) (t 
= 3.4, p = 0.01; Figure 3). Participants showed a significantly higher HbA1c in visit 3 in 
2018 (6.950.1) than in visit 1 in 2018 (6.70.1) (t = -4.4, p = 0.0002; Figure 3). 
 
Figure 4. HbA1c Change in Engaged Participants in City of Austin Diabetes Control 
 
Discussion 
This study assessed the change in HbA1c, a measure of glucose control, over time 
engaged in the City of Austin Diabetes Control Program. In 2018, participants engaged in 
the COA DCP had an average baseline that is considered controlled (6.7 1.3) but there 

























not education included during the visits, rather just the initial 8-hour class before the start 
of the program.  
 In 2019, participants engaged in the COA DCP significantly improved HbA1c from 
baseline (visit one) to visit two (Figure 3). Although these improvements might not be 
clinically significant because the average baseline HbA1c was considered controlled 
(HbA1c < 7). The largest change in HbA1c occurred after the first visit or the initiation of 
the new program. During this visit the participant receives a blood glucose monitor and 
testing supplies as well as the initial pillar of education and the incentive for free 
medication is activated.  
The HbA1c change from visit two to visit three during 2019 was a slight increase 
but not clinically significant (Figure 3). The changes seen in the COA DCP are less than a 
1% reduction in HbA1c, which may not lead to initial cost savings. A 1% reduction in 
HbA1c leads to a 2% reduction in all health care costs and a 13% reduction in diabetes 
related costs (Lage & Boye, 2020). Baseline HbA1c values for both groups were both 
considered controlled (HbA1c<7) according to the Diabetes Standards of Care (Standards 
of Medical Care in Diabetes, 2019). Long-term follow-up may lead to more significant 




CHAPTER VII: STUDY #3 
Evaluating Cardiovascular Biomarkers and Healthcare Utilization in 
Response to a Pharmacist Led Medication Therapy Disease Management Program 
(MTDM). 
Abstract 
Background: Diabetes is a major risk factor for cardiovascular disease and stroke (Malik 
et al., 2007). The objective of this study is to evaluate the cardiovascular clinical 
biomarkers and healthcare utilization of an onsite Medication Therapy Disease 
Management (MTDM) Program. 
Methods: Secondary data evaluation from a prospective cohort enrolled in the City of 
Austin Diabetes Program. 640 City of Austin employees, retirees and dependents enrolled 
in the City of Austin Diabetes Control Program insured by Blue Cross Blue Shield 
insurance. A within-group study design was incorporated, with participants serving as their 
own controls. Cardiovascular clinical biomarkers were evaluated while controlling for 
HbA1c. A total sample size of 2,260 employees’ preventive healthcare claims was used to 
evaluate healthcare utilization in City of Austin employees, retirees, and dependents with 
a diagnosis of diabetes.  
Results: Three cardiovascular related clinical biomarkers (LDL, triglycerides, and total 
cholesterol) were significantly affected by year while controlling for HbA1c. LDL was 
significantly affected by year (t = -2.6, p = 0.01). Participants had a significantly higher 
LDL in 2018 (65.2  1.1 mg/dl) compared to 2019 (60.3  1.1 mg/dl) (t = 3.3, p < 0.01). 
Total cholesterol was significantly affected by year (t = -4.3, p <0.0001). Participants had 
a significantly higher total cholesterol in 2018 (146  0.95 mg/dl) compared to 2019 (136 




year on triglycerides (F = 4.9, p = 0.01). The triglycerides in 2018 decreased by each visit 
but increased from visit 1 to visit 2 in 2019. However, significant differences were only 
found in visit 1 between 2018 (178  4.8 mg/dL) and 2019 (145  4.8 mg/dL) (t = 4.9, p < 
0.01). Employees enrolled in the COA DCP completed significantly more preventive 
healthcare screenings than employees with diabetes not enrolled in the COA DCP. 
Conclusion: There were not significant changes in cardiovascular clinical biomarkers 
between visits during 2019 but there were significant changes in triglycerides, LDL, and 
cholesterol between 2018 and 2019. There may not have been significant changes in 
cardiovascular clinical biomarkers during the 2019 COA DCP in response to the diabetes 
control program because average baseline levels of systolic blood pressure, HDL, LDL, 
and total cholesterol were within normal limits. There may have been small individual 
improvements but not statistically significant. In 2019, employees enrolled in the COA 
DCP completed more preventive healthcare screenings compared to employees with 
diabetes not enrolled in the COA DCP. Prevention of cardiovascular disease can reduce 
disease burden and potentially save costs. Higher engagement in preventive services will 





Diabetes is a major risk factor for cardiovascular disease and stroke (Malik et al., 
2007). Managing blood glucose levels can reduce the risk for micro- and macrovascular 
complications among people with diabetes (Cranor & Christensen, 2003). Maintaining 
HbA1c at 7% or lower is an indicator of successful management of the disease (“Standards 
of Medical Care in Diabetes, 2019). Since diabetes is a lifelong disease, it is important to 
develop self-management skills to maintain blood glucose levels within the targeted range.  
People with diabetes have two to four times increased risk of cardiovascular 
morbidity and mortality compared to people without diabetes (Bertoluci & Rocha, 2017). 
Recent studies show that cardiovascular risk may not be elevated in people with diabetes 
that don’t have other risk factors for heart disease. Stratifying risk for people with diabetes 
based on other measures to treat accordingly can help to reduce overtreating with 
medication. LDL cholesterol is one of the most important CVD risk factors that can be 
influenced by lifestyle changes (Bertoluci & Rocha, 2017). Hypertension is another risk 
factor for cardiovascular disease that can be modified by lifestyle changes (Bertoluci & 
Rocha, 2017). 
During the City of Austin Diabetes Control Program participants are educated about 
lifestyle changes to control HbA1c such as nutrition and exercise. Participants are also 
educated about annual preventive screenings and how this improves disease prevention and 
management. The visit curriculum can be seen in Appendix C. These lifestyle changes 
related to HbA1c may reduce lipids and lower blood pressure if implemented long-term, 
but the cardiovascular related clinical biomarkers of this intervention are currently 




medication management program and found no significant changes in lipids or blood 
pressure but did see reduction in HbA1c (2020). 
Workplace wellness programs invest in preventive services to promote healthier 
lifestyles. There is a growing body of research evaluating preventive services value by 
assessing cost-savings, cost-effectiveness and estimated life-years saved (Maciosek et al., 
2010). Assessing the value added from these services may be a more appropriate method 
to evaluate if they are a good investment. “Good value can be defined as providing 
substantial health benefits per dollar spent net of any savings, without necessarily saving 
money.” (Maciosek et al., 2010). Increasing engagement in preventive screenings has been 
shown to increase life-years saved and costs spent on the services would be recouped 
(Maciosek et al., 2010). 
In addition to teaching self-management skills through the COA Diabetes Control 
Program, participants are also reminded to complete their annual preventive screenings. 
Understanding healthcare utilization for preventive services among this population is of 
interest to see if this education increases engagement in healthcare services compared to 
employees with diabetes not enrolled in the City of Austin Diabetes Control Program. 
The objective of this study is to evaluate the effect the COA DCP on cardiovascular 
variables (Total Cholesterol, LDL, Body Mass, Systolic blood pressure, HDL, 
Triglycerides) while controlling for HbA1c & assess preventive healthcare utilization 
among employees with diabetes enrolled in the City of Austin Diabetes Control Program 
compared to employees with diabetes not enrolled. The working hypotheses are: There will 
be statistically significant differences in cardiovascular biomarkers between 2018 and 2019 




will complete significantly more preventive healthcare screenings compared to employees 
with diabetes not engaged in the 2019 DCP.  
This study is significant because it will evaluate the cardiovascular related clinical 
biomarkers from a MTDM program. People with diabetes are at higher risk for 
cardiovascular disease (Grundy et al., 1999). Modifiable cardiovascular risk factors can be 
influenced by lifestyle intervention to decrease the risk of cardiometabolic disease and 
improve quality of life (Masana et al., 2017). It is our expectation that we will understand 
the cardiometabolic related clinical biomarkers and preventive healthcare utilization in 
City of Austin employees with diabetes enrolled in the Diabetes Control Program. 
Methods 
Secondary data evaluation from a prospective cohort enrolled in the City of Austin 
Diabetes Program and healthcare utilization claims in people with a diagnosis of diabetes. 
A within-group study design was incorporated, with participants serving as their own 
controls. 
Participants 
 640 City of Austin employees, retirees and dependents enrolled in the City of 
Austin Diabetes Control Program insured by Blue Cross Blue Shield insurance. Exclusion 
criteria includes participants with Medicare as a primary insurance policy, employees 
without a diagnosis of diabetes, and less than 18 years of age. In 2019, City of Austin 
reported 17,120 employees in 57 departments with 65% of the population being male. Self-
reported statistics reveal 49% of the population identifies as white, 30% Hispanic or Latino 




healthcare claims was used to evaluate healthcare utilization in City of Austin employees 
and dependents with a diagnosis of diabetes.  
Data Collection 
The City of Austin Diabetes Program partners with a local pharmacy to collect 
biomarkers of participants within the program. These datasets are shared with the City of 
Austin who stores the file in a secure PHI folder within their system. Deidentified datasets 
were provided from the City of Austin for analysis. Aggregate healthcare utilization claims 
for members of the insurance plan with a diagnosis of diabetes were collected from the 
insurance company and shared with the PI. 
 
Statistical Analysis 
Descriptive statistics were completed to understand baseline characteristics of the 
population. Descriptive statistics are reported as mean  sd. Descriptive statistics were 
compared using Student’s t-test. A total sample size of 460 was used to analyze changes in 
cardiovascular disease (CVD) related clinical biomarkers. CVD clinical biomarkers 
include body mass, systolic blood pressure, triglycerides, HDL, and LDL (Frederick et al, 
2020). Linear regression was used to evaluate the effect of the number of completed visits 
(Visit 1, Visit 2 & Visit 3) and year (2018 & 2019) on the cardiovascular clinical 
biomarkers (body mass, LDL, HDL, triglycerides, systolic BP, and total cholesterol) while 
controlling for HbA1c.  
A total sample size of 2,260 employee’s preventive healthcare claims was used to 
evaluate healthcare utilization. Two proportion Z-tests were used to analyze the differences 




and employees with diabetes that are not enrolled. Statistical significance is defined as P < 




Participants’ characteristics are described in Table 8. The total number of 
participants was 640, with each variable sample size listed for the baseline values. Pairwise 
deletion was used to remove missing data or incorrect entries. Most participants had 
baseline HbA1c values < 7% at baseline with averages for 2018 & 2019 respectively (6.7 
 1.3 & 6.9  1.3). There were significant differences between 2018 & 2019 baseline values 
in body mass (2018: 98.1 22.3 kg; 2019: 97.1  21.1 kg), HbA1c (2018: 6.7 1.3; 2019: 
6.9  1.3), LDL (2018: 54.4  23.9 mg/dL; 2019: 49.8  22.3 mg/dL), total cholesterol 
(2018: 146.6 34.2 mg/dL; 2019: 137.2 34.9mg/dL) and triglycerides (2018: 175.9 
100.2 mg/dL; 2019: 144.790.6 mg/dL) between groups (p<0.05). 
 




2018 Baseline 2019 Baseline 











34.2  7.6 
6.7  1.3 
54.4  23.9 
175.9 100.2 
126.9  17.0 
33.9  7.0 
6.9  1.3 * 
49.8  22.3 * 
144.7  90.6 * 
127.1  17.3 
Diastolic BP 418 76.9 10.8 76.6 11.5 
HDL 300 64.6 26.5 64.2  25.1 
Total Cholesterol 418 146.634.2 137.234.9* 
 Note: Data are reported as meansd (*) Significantly different 




BMI = body mass index; HbA1c = glycated hemoglobin; HDL = high-density lipoproteins LDL = 
low-density lipoproteins; BP= blood pressure.  
 
Cardiovascular Results 
Three cardiovascular related clinical biomarkers (LDL, triglycerides, and total 
cholesterol) were significantly affected by year while controlling for HbA1c. LDL was 
significantly affected by year (t = -2.6, p = 0.01). Participants had a significantly higher 
LDL in 2018 (65.2  1.1 mg/dL) compared to 2019 (60.3  1.1 mg/dL) (t = 3.28, p < 0.01) 
with pooled data of visit and controlling for HbA1C (Figure 4). Total cholesterol was 
significantly affected by year (t = -4.30, p <0.0001). Participants had a significantly higher 
total cholesterol in 2018 (146  0.95 mg/dl) compared to 2019 (136  0.95 mg/dL) (t = 6.9 
p < 0.0001) with pooled data of visit and controlling for HbA1C (Figure 5).  There was a 
significant interaction effect of visit and year on triglycerides (F = 4.9, p = 0.01) (Figure 
6). The triglycerides in 2018 decreased by each visit but increased from visit 1 to visit 2 in 
2019. However, significant differences were only found in the visit 1 between 2018 (178 
 4.8 mg/dL) and 2019 (145  4.8 mg/dL) (t = 4.9, p < 0.01). There was no significant 




Figure 5. LDL Change in Engaged Participants in City of Austin Diabetes Control Program 
while Controlling for HbA1c 
 
 
Figure 6. Total Cholesterol Change in Engaged Participants in City of Austin Diabetes 


















































Figure 7. Triglycerides Change in Engaged Participants in City of Austin Diabetes Control 




 As seen in the figures above, the cardiovascular related clinical biomarkers LDL 
cholesterol and total cholesterol improved between year 2018 and 2019, although both of 
these biomarkers were within recommended range at baseline. Triglycerides also improved 
between 2018 and 2019, but the baseline level for 2018 participants was not within 
recommended range. Small changes in these numbers are positive but not clinically 
significant because of the baseline number already within recommended range. Therefore, 
maintaining these values within recommended range is a positive outcome. 
























645 employees with diabetes who were enrolled in the Diabetes Control Program 
and 1,615 employees that have been identified as diabetic in the claims data but were not 
enrolled in the 2019 City of Austin Diabetes Control Program had preventive healthcare 
utilization claims. These claims were analyzed to understand if employees with diabetes 
enrolled in the COA DCP engaged in more preventive screenings during 2019 compared 
to employees with diabetes on the healthcare plan that were not enrolled in the COA DCP. 
Employees enrolled in the COA DCP completed significantly more preventive healthcare 
screenings than employees with diabetes that were not enrolled in the COA DCP (Table 
9).  
Table 9. Preventive Healthcare Utilization in City of Austin Employees with Diabetes 
Preventive Screening 
Percentage enrolled in DCP 
(n=645) 
Percentage not enrolled in 
DCP (n= 1,615) 
Annual Physicals  39.1% * 21.9% 
PCP Visits 72.7% * 54.2% 
Eye Exams 37.1% * 17.6% 
HbA1c Screenings 67.4% * 52.1% 
Creatinine Screenings 7.1% * 4.0% 
Cholesterol Screenings 62.3%* 46.2% 
Breast Cancer Screenings 70.0%* 30.7% 
Colon Cancer Screenings 11.9%* 6.3% 
Cervical Cancer Screenings 23.4%* 17.6% 
   
(*) Significantly different between groups, p < .05 as performed with the two proportion Z-test 
statistic Note: Cancer screening percentages only include members eligible for those screenings 
based on age and gender. 
Discussion 
Triglycerides decreased significantly from visit 1 in 2018 to visit 1 in 2019. This 
timeframe is a year of being engaged in the 2018 program and receiving free medication 




with targeted education around glycemic control and nutrition, triglycerides might have 
improved (Odea, 1984). This may be due to better self-management and lifestyle changes. 
Poor glycemic control is associated with higher triglyceride levels (Zheng et al., 2018). 
HbA1c values at baseline were within the recommended range. The change in triglycerides 
may be from other positive lifestyle changes in response to the COA DCP such as exercise 
or changing dietary patterns. 
Total cholesterol and LDL cholesterol were lower at the baseline of 2019 compared 
to baseline of 2018. Since these participants had already finished a year of medication 
management for diabetes and visits with a nurse, they may have also improved their 
cholesterol levels through lifestyle changes. The initial 8-hour class required at the 
beginning of the 2018 program has an entire section of education relating the heart healthy 
choices. Overall, the population engaged in the City of Austin Diabetes Control Program 
is already within target range for American Diabetes Association (ADA) clinical practice 
recommendation with their average LDL<100 mg/dL and their average total cholesterol 
<200 mg/dL (Standards of Medical Care in Diabetes, 2019). 
Systolic blood pressure, weight, and HDL did not have any significant interaction 
with year or visit when controlling for HbA1c. Baseline HDL for both 2018 & 2019 is 
within target range with averages of 64.6   25.5 mg/dL & 64.2   25.1 mg/dL respectively 
(Standards of Medical Care in Diabetes, 2019). Systolic blood pressure is barely elevated 
at baseline for both 2018 & 2019 with averages being 126.9  17.0 & 127.1  17.3 




biomarkers there may need to be targeted education to change these secondary endpoints. 
Since diabetes is a risk factor for cardiovascular disease and these clinical biomarkers are 
modifiable risk factors for cardiovascular disease, in the future, additional education about 
lifestyle for preventing heart disease should be included in the visits with the pharmacist. 
Another reason there may not be a significant interaction is because the baseline values 
were already within normal range for most of the cardiovascular biomarkers.  
Data from the American Diabetes Association (ADA) clinical practice 
recommendations using the National Health and Nutrition Examination Survey 
(NHANES) was evaluated to determine percentage of adults who meet clinical guidelines 
set by the ADA between 1999-2002 (Resnick et al., 2006). Over half of adults with diabetes 
reported hypertension and 24% of those individuals reported cardiovascular disease 
(Resnick et al., 2006). Since the prevalence of hypertension and cardiovascular disease in 
this population is high, measuring these clinical risk factors within a diabetes management 
program is important.  
There may not have been significant changes in cardiovascular clinical biomarkers 
during the 2019 COA DCP in response to the diabetes control program for two possible 
reasons. First, average baseline levels of systolic blood pressure, HDL, LDL and Total 
Cholesterol were within normal limits. There may have been small individual 
improvements but not statistically significant. Second, the education provided during the 
2019 program curriculum was not specific to change these clinical markers, rather focused 




Preventive health care services typically don’t show immediate value and costs tend 
to be highest initially (Dehmer et al., 2017). Prevention of cardiovascular disease can 
reduce disease burden and potentially save costs and screening for lipids and blood pressure 
are at the top preventive services for health impact or net difference for quality adjusted 
life years (QALYs) (Dehmer et al., 2017). These two screenings are included in the 
quarterly visit for the COA DCP and may be increasing value added to employees, but 
clinical biomarkers are not significantly changing within one year of the program. Long-
term evaluation may show positive impact on QALY or cost-effectiveness of these 
screenings within the COA DCP (Dehmer et al., 2017). Maeng et al., evaluated a MTDM 
program and showed that patients engaged had lower percentages of hospital admissions 
and lower medical costs. Long-term follow-up in the COA DCP may show similar results 
for cost savings. 
Employees with diabetes enrolled in the COA DCP completed significantly more 
preventive healthcare screenings in every category compared to employees with diabetes 
on the health insurance plan that were not enrolled in the COA DCP. Preventive healthcare 
screenings have shown to increase life-years saved and costs spent on the services would 
be recouped (Maciosek et al., 2010). Preventive healthcare utilization has been shown to 
prevent number of deaths, with the greatest impact with preventive healthcare services that 
reduce the risk for cardiovascular disease (Farley et al., 2010).  
Cueller et al., found that Hispanics and African Americans were less likely than 




preventive screenings (2017). Incentives failed to narrow preventive service gaps among 
races. Future research should include demographic information to measure the impact of 




CHAPTER VIII: DISCUSSION 
 
 These studies were conducted to determine: 1) baseline characteristics of 
participants enrolling in the City of Austin Diabetes Control Program and better understand 
engagement, 2) changes in blood glucose control among participants engaged in the City 
of Austin Diabetes Control Program, 3) changes in cardiovascular biomarkers among 
participants engaged in the City of Austin Diabetes Control Program and 4) preventive 
healthcare utilization among employees with diabetes on the City of Austin health 
insurance plan. 
 In study 1, 64% (2018) & 59% (2019)  of the participants enrolled in the COA DCP 
had baseline HbA1c levels that were considered controlled, which is higher than the 
American population reports of 50% according to the ADA (National diabetes Statistics 
Report, 2020). The City of Austin Diabetes Control Program also had a high percentage of 
engagement during both 2018 (85%) & 2019 (86%). 54% of U.S. adults that self-identified 
receiving a diagnosis of diabetes reported engaging in a Diabetes Self-Management 
Education Program (DSME) (Adjei Boakye et al., 2018). The percentage of City of Austin 
Employees that have diabetes is currently unknown because this metric was not shared 
from the health insurance company. Measuring total cases of diabetes on the City of Austin 
insurance plan in future studies can help to understand the percentage of the diabetic 
population the program is reaching as well as inform future campaigns to increase 




Using data from 2011-2013 Behavioral Risk Factor Surveillance System (BRFSS), 
people engaging in a diabetes self-management education (DSME) were significantly more 
likely to be physically active, engage in at home blood glucose monitoring and conduct 
home foot examinations (Adjei Boakye et al., 2018). Diabetes Self-Management Education 
Programs are a key component to improve health biomarkers and finding ways to increase 
participation and engagement in these programs can have a significant impact on public 
health measures to mitigate long-term complications from uncontrolled diabetes (Adjei 
Boakye et al., 2018).  
Sociodemographic characteristics of participants in the COA DCP were not 
collected and this is a major limitation of the current study and a direction for future 
research. Adjei Boayke el al., found that higher education and greater household income 
were associated with increased engagement in DSME (2018). Males and Hispanics were 
less likely to engage in DSME (Adjei Boakye et al., 2018). Evaluating these factors within 
the City of Austin population can help to inform future campaigns to engage populations 
that are less likely to participate. 
 In study two, participants engaged in the 2019 COA DCP significantly improved 
HbA1c from baseline (Figure 2). The largest decrease in HbA1c occurred after the first 
visit or the beginning of the new curriculum in 2019. Baseline HbA1c values in 2018 (6.7 
 1.3) & 2019 (6.9 1.3) were both considered controlled (HbA1c<7 %) according to the 
Diabetes Standards of Care (Standards of Medical Care in Diabetes, 2019). 64% in 2018 




considered controlled compared to only 22.3% of another Diabetes Self-Management 
Program of a similar size (Lorig et al., 2016). Poor glycemic control following diabetes 
diagnosis is associated with worse outcomes. Longer periods of HbA1c levels ≥ 8.0% were 
associated with increased microvascular events and mortality risk (Laiteerapong et al., 
2018). HbA1c reduction is associated with a slower rise in healthcare costs over time 
(Bansal et al., 2018). Screening to identify pre-diabetes and diabetes as well as diabetes 
self-management programs are critical aspects of workplace wellness programs to prevent 
long-term complications of uncontrolled diabetes. 
Sepah et al., evaluated long-term engagement and clinical outcomes from a digital 
diabetes prevention program and found that 3 years of engaging in the program participants 
had significantly lower HbA1c and weight compared to baseline (2017). This shows the 
digital delivery method was able to keep participants engaged and resulted in sustained 
long-term change. Long-term clinical outcomes for the COA DCP should be measured to 
understand if the positive changes seen during the two years measured can be sustained 
long-term. A digital version of the program that implements telemedicine and evaluate 
clinical changes to measure differences between in-person and remote options for future 
wellness programming may be a viable option. 
 In study three, the cardiovascular disease (CVD) related clinical biomarkers 
triglycerides, total cholesterol and LDL significantly decreased from 2018 to 2019 while 
controlling for HbA1c. The other CVD related clinical biomarkers HDL, blood pressure 




cardiovascular disease risk through lifestyle changes is not part of the COA DCP 
curriculum although many features of the lifestyle changes for diabetes management 
overlap with reducing CVD related risk factors, such as increasing physical activity and 
improving nutrition. Improving carbohydrate choices, managing portions, and increasing 
physical activity will not only improve glycemic control but also reduce triglycerides 
(Newman et al., 2017).  
An important clinical feature of the participants in the DCP is that some of the 
cardiovascular clinical biomarkers were within target recommendations at baseline 
(LDL<100 mg/dL, HDL>60 mg/dL) (Diabetes Standards of Care, 2019). The change seen 
within this group might not be significant due to the baseline values being within the 
recommended range, similar to the HbA1c values. Less than 50% of the adult population 
with Type 2 Diabetes meet the recommended clinical guidelines for the prevention of CVD 
(Newman et al., 2017). The average CVD related clinical risk factors in the COA DCP 
population are mostly within range. Comparing the average CVD clinical markers in the 
whole City of Austin Employee population to people engaged in the COA DCP would be 
of interest to see if a higher percentage of DCP participants meet these CVD clinical 
recommendations. Future research should include long-term follow-up to see if COA DCP 
participants maintain these CVD related risk factors within clinical recommendations. 
 These three studies together suggest that the engagement among participants 
enrolling in the COA DCP is high. The glucose control among engaged members is 




of the clinical recommendations from the Diabetes Standards of Care (2019). Managing 
clinical risk factors can reduce the risk of developing complications related to diabetes 
years later (Lian et al., 2017). The cardiovascular related clinical biomarkers were mostly 
within recommended range and triglycerides, total cholesterol and LDL cholesterol 
significantly improved from 2018 to 2019.  
The COA DCP participants also had higher percentages of preventive healthcare 
screenings which may contribute to good glycemic control and clinical cardiovascular risk 
factors within range seen in this population. Evidence suggests that for most patients with 
Type 2 Diabetes, a goal of maintaining a HbA1c <7% can reduce the risk for future 
microvascular disease risk (Newman et al., 2017). Monitoring chronic diseases are part of 
the best practice recommendations for municipal wellness programs but less than half of 
the municipalities report monitoring diabetes (Sabharwal et al., 2019). Monitoring 
behaviors and chronic conditions may be costly for wellness programs, but this is one area 
of wellness programs that have been shown to lead to better biomarkers. The City of Austin 
Diabetes Program monitors this chronic condition and offers education about self-
management and lifestyle changes to better control diabetes. Overall, this wellness program 
has shown to have high engagement, great glycemic control within the engaged population, 
almost all cardiovascular related risk factor clinical biomarkers within recommended range 







This research is the first to our knowledge to examine the clinical biomarkers and 
preventive healthcare utilization outcomes of an incentivized pharmacist-led medication 
therapy disease management (diabetes) program in a municipality. Municipalities face 
unique challenges due to the diversity of professions and dispersed worksites throughout 
the city (Morgan et al., 2011). This model of wellness program utilizes local pharmacy 
locations in addition to worksites to make the services available to all employees. The 
structure of the program also allows individuals longer appointments with a healthcare 
professional to provide education and self-management skills to control diabetes. The 
incentive structure of the program provides free medication, which removes the barrier of 
cost that is commonly associated with noncompliance of medication in diabetes. Overall, 
this subgroup population has shown to have very good glycemic control and cardiovascular 
risk factors within target range.  
Bias 
There are a few areas of potential bias with the present study. The pharmacist-led 
visits were provided free of charge to patients and funded through the health plan at the 
workplace (like a “closed” network).  This program is also incentivized by providing 
medication free of charge to participants that meet the requirements. 
The enrollment in the program is voluntary. The program is also highly incentivized 
which can skew engagement to people that need the benefit. Evaluating workplace wellness 




available to compare another diabetes program or a similar program in a different 
population. We have designed this study to use participants to serve as their own control. 
Limitations 
 The results of the current dissertation will be limited to City of Austin 
employees, dependents and retirees enrolled in the Diabetes Control Program that live in 
the southern United States. However, the results will elucidate the effectiveness to improve 
clinical biomarkers in response to this model of workplace wellness program within the 
COA population, which is invaluable information.  
Demographic, age, and sex information was not collected as part of the City of 
Austin Diabetes Program. This missing data limits the ability to stratify analysis to 
understand differences in demographics, age, and sex. The percentage of male and self-
identified demographics of the City of Austin Employee population has been provided. A 
systematic review was conducted to evaluate if diabetes self-management education 
improved glycemic control in Hispanic patients and the outcomes showed a -0.25% 
reduction in HbA1c post-intervention (Ferguson, Swan & Smaldone, 2015). This reduction 
within HbA1c is greater than the reduction seen within the 2019 COA DCP (-0.09).  
Another limitation to this study is the results do not differentiate between type 1 
and type 2 diabetes. Type 2 diabetes accounts for 90-95% of all diabetes cases according 
to the CDC (National diabetes Statistics Report, 2020). Therefore, the results from this 
study are most likely to be representative of type 2 diabetes. Medications prescribed to 




include prescriptions and dosing to better understand the cost of the program and be able 
to calculate return on investment. This study can be the framework for future research in 
workplace wellness within municipalities. 
Future Research 
 The City of Austin Diabetes Control program has a high percentage of employees 
with a HbA1c <7% and a large percentage of participants that enroll in the program stay 
engaged by completing three or more visits in a calendar year (85% in 2018 & 86% in 
2019). Understanding the trends of glucose control within all employees with diabetes on 
the City of Austin insurance plan would be of interest to measure how HbA1c varies 
between participants enrolled in the COA DCP compared to those that are not. Working 
with the insurance carrier to obtain these aggregate trends in HbA1c for the whole 
population while protecting individual privacy would be impactful for future evaluation.  
 Stratifying the Diabetes Control Program by glycemic control in the future is of 
interest. For example, participants that have a controlled HbA1c <7% at baseline would 
complete two visits during the calendar year (one visit every 6 months) and participants 
that had an uncontrolled HbA1c ≥7% would complete the 3+ visits to be considered 
engaged (the current model). If participants that have glycemic control at baseline are able 
to maintain glycemic control with less visits, this is a cost-saving attribute for the City of 
Austin. Tailoring the intervention to the population needs is important, and future research 
is needed to understand what the best intervention timeline is for optimal glycemic control 




In the future, it is recommended that in addition to the clinical data collected during 
the visits, the initial visit will also include collection of demographic information, including 
age, sex, and ethnicity. Missing this demographic information was a limitation because 
without it, measuring engagement characteristics was difficult. It is important to understand 
the differences in the population demographics of those staying engaged in the program 
compared to those that do not complete the program. Studying trends in engagement can 
help future promotion of the program to target high risk populations that may not be 
enrolling or staying engaged. 
Adapting wellness interventions to be available during teleworking is more 
important than ever following the COVID-19 Pandemic. The ability to reach employees 
outside of the traditional workplace is the future of wellness and utilizing telemedicine can 
be effective at improving clinical outcomes (Margolis et al., 2013). Measuring changes 
between 2019 and 2020 during the COVID-19 Pandemic is an important next step to 
understand how engagement changed during this time. This information can help guide 
future planning to allow this program to adapt to reach participants remotely through 
telemedicine. 
Evaluating the educational component delivered during the pharmacy visits for 
increased knowledge and increased self-efficacy regarding diabetes disease management 
is important in future studies.  Huang et al., reported self-efficacy of medication use being 
positively associated with diabetes medication adherence which leads to better HbA1c 




participants to have access to individual diabetes education and medication management 
while monitoring changes in HbA1c and lipids quarterly. The time spent at a pharmacy 
visit during this program discussing personal labs, medications and health behaviors is 
much longer than a typical appointment with a general physician (Kosecoff et al., 1990).  
The diabetes empowerment scale is a tool developed to measure diabetes related 
psychosocial self-efficacy (Anderson et al., 2000). This tool can be added to the baseline 
data and annual follow-up to measure changes in diabetes related self-efficacy in response 
to the COA DCP. 
Overall, the City of Austin Diabetes Control Program evaluation shows that clinical 
markers related to diabetes management and cardiovascular disease are within 
recommended ranges for most of the population, according to the Diabetes Standards of 
Care. Future research should understand the influence of sociodemographic factors and 
long-term impact on clinical markers. The educational component included in the COA 
















Diabetes Control Program (DCP) 
Take charge of your health with year-round diabetes support, 
and receive $0 copay diabetes medication & supplies. 
Schedule and attend your first                              
appointment with a Randalls Pharmacist 
to get enrolled in the program.  
Attend a Randalls visit every 3 months 
for diabetes screenings and pharmacy 
support.  
Contact HealthyConnections  
512-974-3284  
HealthyConnections@austintexas.gov  
Annual Program Requirements 
 Must be on a City medical plan  
 Attend at least 3 Randalls screenings  
 Complete online health assessment at BCBSTX.com 
 
 




Receive diabetes medications and testing       
















CONSENT TO PARATICIPATE AND RELEASE MEDICAL INFORMATION 
 
I am voluntarily participating in The City of Austin Diabetes Control Program (DCP). My 
participation will require that my pharmacist obtain and share certain medical/health 
information about my condition from my physician and/or other members of my health care 
team including City of Austin employee benefits staff.  By signing this form, I am giving my 
authorization for my medication information to be shared with my pharmacist, my physician(s) 
office, the DCP coordinator, City of Austin Employee Benefits Division or health care providers 
participating in my care, to be used specifically and confidentially for my care, to assess quality 
of care and to administer the program. Further, I give my authorization that data 
appropriately de-identified to protect my identity and condition may be aggregated with 
similarly blinded data from other patients enrolled in the same program for research and 
educational proposes. “De-identified” data means health information that does not identify an 
individual and with respect to which there is no reasonable basis to believe that the 
information can be used to identify an individual in accordance with the Health Insurance 
Portability and Accountability Act. 
 
I understand that I may revoke this authorization at any time by giving written notice to The 
City of Austin. In such case, I understand and agree that actions taken by any party related to 
the DCP program that relied upon my prior consent would stand. Also, I understand that if 
this consent is not revoked, it will continue for the time period that I am enrolled in the 
program and will expire automatically should I discontinue my participation in DCP program. 
 
I understand that I am required to sign this authorization as a condition of my participation in 
the Diabetes Control Program. 
 
I understand that the information disclosed by this authorization may be subject to re-
disclosure by the recipients listed above and, in that case, will no longer be protected by the 
Health Insurance Portability and Accountability Act Privacy Rule [45 CFR Part 164], and the 







Participant Signature: ________________________________  Date:  _____________  
 
PLEASE PRINT   
 
First Name: ___________________________    Last Name: ___________________________                
 
Employee ID Number (if applies):  __________________ 
 
Date of Birth: _______________________                        Last 4 of SSN: 
               
Email address: __________________________________________  
 







































Appendix D: Data Use Agreement 
 
DATA USE AGREEMENT 
UTA 11-___ 
This Data Use Agreement (the “DUA”) is entered into between the Parties identified 
below.  In consideration of the mutual covenants and premises contained herein, the 
parties hereby agree as follows:  
 
The Terms and Conditions for Data Use Agreement attached hereto as Exhibit A are 
incorporated herein by reference in their entirety (the “Terms and Conditions”).  
Capitalized terms used in this DUA without definition shall have the meanings given to 
them in the Terms and Conditions.   In addition to the signatures of each Party identified 
in Section 1, signature is also required from the Contact Person for The University of 
Texas at Austin. 
 
1.  Parties (name, address for notice)  
The University of Texas at Austin 
(“University”) 
Attn:  [John Batholomew] 
Addr:  2109 San Jacinto Blvd, Austin, TX 
78712 
Phone: 512 232 602 
[information for UT College responsible 
for LDS exchange] 
[City of Austin Healthy Connections] 
Attn: Chris Vykukal 
Addr: 505 Barton Springs Rd. 
 Austin, TX 78704 
Phone:    512-585-7811 
 
2.  Party’s Contact Person (name, address for exchanging information) 
For University – Principal Investigator 
Name: Dr. Harold W. (Bill) Kohl  
 
Addr: 1616 Guadalupe, Suite 6.300 
Austin, Texas 78701 
Phone:    512-944-4118 
Email:     harold.w.kohl@uth.tmc.edu  
 
For City of Austin Healthy Connections 
Name: Chris Vykukal 
Addr: 505 Barton Springs Rd. 
 Austin, TX 78704 
Phone:    512-585-7811 
Email:     chris.vykukal@austintexas.gov 
 
 
3.  General Terms 
Purpose The Purpose of this DUA is to provide Recipient with access to 
a Limited Data Set (“LDS”) for use by Recipient as described 
in Section 5, below, and Section 5 of Terms and Conditions. 
Effective Date  
March 1, 2021 
Agreement Term From the Effective Date for so long as Recipient retains the 








4.  Disclosing Party (“Covered Entity”) Information  
Name of Covered Entity Description of  Limited Data Set provided by 
Covered Entity 
City of Austin Wellness Program 
Coordinator- Chris Vykukal  
De-identified clinical dataset from the City of 
Austin Diabetes Program including: Height, 
weight, A1c, Total Cholesterol, HDL, LDL, 
Triglycerides, blood pressure. 
 
 
5.  Receiving Party (“Recipient”) Information  
Name of Recipient Description of Recipient’s Use of the LDS 
Lauren McGill MS, RD, CSSD, LD Dissertation “Engagement in a Diabetes Management 





6.   This Agreement may be signed in separate counterparts, and facsimile and 




IN WITNESS WHEREOF, the parties hereto have caused their duly authorized 




The University of Texas at Austin 
College of   
Department of Education 
 
 Lauren McGill 
By                 ________________ 
Name Lauren McGill 
Title MS, RD, CSSD, LD 
 
Date  3/1/2021 
 
 
[City of Austin Wellness Coordinator 
 
By  Chris Vykukal, CHES 
Name  Chris Vykukal 
Title  Wellness Coordinator  














By:  _ _______  _2 March 2021___________ 








TERMS AND CONDITIONS FOR 
DATA USE AGREEMENT 
These Terms and Conditions (“Terms and Conditions”) are attached to and incorporated into a 
Data Use Agreement (“DUA”). All Section number references in these Terms and Conditions 
shall be references to provisions in these Terms and Conditions unless explicitly stated otherwise. 
 
Background 
Covered Entity identified in the DUA own rights in such Party’s Limited Data Set (“LDS”).  
Covered Entity considers it desirable to make Party’s LDS available to Recipient for pursuing the 
Purpose identified in the DUA, subject to the terms and conditions hereof.  
1.  Definitions.  Unless otherwise specified in this Agreement, all capitalized terms used 
in this Agreement not otherwise defined have the meaning established for purposes of 
the “HIPAA Regulations” codified at Title 45 parts 160 through 164 of the United States 
Code of Federal Regulations, as amended from time to time. 
2.  Preparation of the LDS.  Covered Entity shall prepare and furnish to Recipient a LDS 
in accord with the HIPAA Regulations or Covered Entity shall retain Recipient as a 
Researcher (pursuant to an appropriate and separate Agreement) and direct Recipient, 
as its Researcher, to prepare such LDS.    
3.  Minimum Necessary Data Fields in the LDS.  In preparing the LDS, Covered Entity or 
Researcher shall include the data fields specified by the parties from time to time, which 
are the minimum necessary to accomplish the purposes set forth in Section 5 of this 
Agreement.    
4.  Responsibilities of Recipient.  Recipient agrees any disclosure of LDS is made in the 
strictest confidence and to: 
Use or disclose the LDS only as permitted by this Agreement, as required by law, 
or otherwise authorized in writing by Covered Entity; 
Safeguard the LDS according to commercially reasonable administrative, physical and 
technical standards (e.g., National Institute of Standards and Technology, Center for 
Internet Security, Gramm-Leach Bliley Act) to prevent use or disclosure of the LDS 
other than as permitted by this Agreement or required by law, including all 
reasonable efforts to ensure the protection, confidentiality, and security of any LDS of 
Covered Entity in its possession, such efforts to be no less than the degree of care 
employed by Recipient to preserve and safeguard its own confidential information, but in 
no event less than a reasonable degree of care; 
Continually monitor its operations and take any action necessary to assure the LDS is 
safeguarded in accordance with the terms of this Agreement; 
Provide written notice to Covered Entity of any use or disclosure of the LDS of 
which it becomes aware that is not permitted by this Agreement or required by 
law, within one (1) business day after discovery of misuse or 
disclosure.  Recipient will promptly provide all information requested by Covered 
Entity regarding the impermissible use or disclosure; 
Require any of its subcontractors or agents that receive or have access to the 
LDS to agree to the same restrictions and conditions on the use and/or 






Not use the information in the LDS to identify or contact the individuals who are 
data subjects.  
Follow the terms of this Agreement in addition to any official policies and standards of 
University, or their functional equivalent.  University policies and standards include, but 
are not limited to, the Information Resources Use and Security Policy1, the Acceptable 
Use Policy2, the Minimum Security Standards for Systems3, the Minimum Security 
Standards for Application Development and Administration4, the Data Classification 
Standard5, the Data Encryption Guidelines6, the Minimum Security Standards for Data 
Stewardship7, and Protecting Sensitive Research Data8.  Any safeguards in this 
agreement complement University policy and provide specific guidance for research and 
business practices, but do not preclude Recipient from adhering to University policy.  
 
In addition to any other termination rights set forth in this Agreement and any other rights 
at law or equity, if Covered Entity reasonably determines that the Recipient has 
breached any restrictions or obligations set forth in this section 4, Covered Entity may 
immediately cancel this, and any other, Agreement for item(s) or services(s) involving 
the LDS without notice or offer to cure. 
 
5.  Permitted Uses and Disclosures of the LDS.   
 a)   Recipient may use and/or disclose the LDS for its Research and Public 
Health            activities and the Health Care Operations of the Covered Entity, 
specifically including conducting a research Study entitled ““Engagement in a Diabetes 
Management Program & Clinical Biomarkers in Diverse Municipality Workers”. 
Recipient may use the LDS only in accordance with the purposes and procedures set 
forth in the Study protocol. 
b)  At the request of the Covered Entity, Recipient agrees to provide Covered entity a 
written summary of the procedures the Recipient uses to safeguard LDS.    
 
6.  Term and Termination. 
Term.  The term of this Agreement shall commence as of the Effective Date and 
shall continue for so long as Recipient retains the LDS, unless sooner terminated 
as set forth in this Agreement. 
Termination by Recipient.  Recipient may terminate this agreement at any time 
by notifying the Covered Entity and returning or destroying the LDS.   
Termination by Covered Entity.  Covered Entity may terminate this agreement at 















For Breach.  Covered Entity shall provide written notice to Recipient within ten 
(10) days of any determination that Recipient has breached a material term of 
this Agreement.  Covered Entity shall afford Recipient an opportunity to cure said 
alleged material breach upon mutually agreeable terms.  Failure to agree on 
mutually agreeable terms for cure within thirty (30) days shall be grounds for the 
immediate termination of this Agreement by Covered Entity. 
Effect of Termination.  Sections  4, 5, 6(e) and 7 of this Agreement shall survive 
any termination of this Agreement under subsections (6)c or (6)d.   
Disposition of LDS.  Upon the first to occur of 1)  Termination of this Agreement or 2) 
completion of the Purpose of this Agreement, Recipient shall return the LDS to Covered 
Entity and certify destruction of any portion of the LDS not returned. 
 
7.  Miscellaneous. 
Change in Law.  The parties agree to negotiate in good faith to amend this 
Agreement to comport with changes in federal law that materially alter either or 
both parties’ obligations under this Agreement.  Provided however, that if the 
parties are unable to agree to mutually acceptable amendment(s) by the 
compliance date of the change in applicable law or regulations, either Party may 
terminate this Agreement as provided in section 6. 
Construction of Terms.  The terms of this Agreement shall be construed to give 
effect to applicable federal interpretative guidance regarding the HIPAA 
Regulations. 
 
No Third Party Beneficiaries.  Nothing in this Agreement shall confer upon any 
person other than the parties and their respective successors or assigns, any 
rights, remedies, obligations, or liabilities whatsoever. 
Counterparts.  This Agreement may be executed in one or more counterparts, 
each of which shall be deemed an original, but all of which together shall 
constitute one and the same instrument. 
Headings.  The headings and other captions in this Agreement are for 
convenience and reference only and shall not be used in interpreting, construing, 
or enforcing any of the provisions of this Agreement. 
Other Provisions.   The Agreement will be governed by the laws of the State of Texas, 
without regard to choice of law principles. No amendment to the Agreement will be 
effective unless in writing and signed by the Parties. Neither the Agreement nor the 
rights and obligations of the Parties hereunder may be sold, assigned or otherwise 
transferred. If any provision of the Agreement is held to be unenforceable, all other 
provisions will continue in full force and effect. The Agreement supersedes any and all 
prior understandings or previous agreements between the Parties, oral or written, 
relating to the subject matter herein and constitutes the sole and complete agreement 
between the Parties related to the subject matter hereof.  Any delay by a Party to 
enforce any right under the Agreement shall not act as a waiver of that right, nor as a 
waiver of the Party’s ability to later assert that right relative to any particular factual 






waiver of sovereign immunity by Parties that are state agencies. 
 
 







Appendix E: IRB Proposal 
 
Office of Research Support & Compliance
Institutional Review Board 
P.O. Box 7426, Campus Code A3200
Austin, Texas 78713 
T: 512-232-1543      F: 512-471-8873
Email: irb@austin.utexas.edu
www.research.utexas.edu/ors




2109 SAN JACINTO BLVD
AUSTIN, TX 78712
+1 512 391 2530
hk5689@eid.utexas.edu
Dear Harold Kohl:
On 3/8/2021, the IRB reviewed the following submission:
Type of Review: Initial Study
Title of Study: Engagement in a Diabetes Management Program & 






IND, IDE, or HDE: None
Documents Reviewed: • Diabetes Consent form, Category: Consent  Form;
• Diabetes Flier, Category: Recruitment Materials;
• DUA, Category: Other;
• McGill_IRB.docx, Ca tegory: IRB Protocol;
The IRB determined that the proposed activity is not research involving human subjects 
as defined by DHHS and FDA regulations. The activity was determined to be NHSR: 
PI/PIP confirmed data is de-identified, no interaction with participants; DUA provided.
IRB review and approval by this organization is not required. This determination applies 
only to the activities described in the IRB submission and does not apply should a ny 








Office of Research Support & Compliance
Institutional Review Board 
P.O. Box 7426, Campus Code A3200
Austin, Texas 78713 
T: 512-232-1543      F: 512-471-8873
Email: irb@austin.utexas.edu
www.research.utexas.edu/ors
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would be considered human subject research, please contact the Office of Research 
Support and Compliance at irb@austin.utexas.edu.
Sincerely,
Institutional Review Board
University of Texas at Austin
cc:
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